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ABSTRACT  
Introduction: Ventricular arrhythmias (VAs) are common after an acute coronary 
syndrome (ACS) and are associated with worse clinical outcomes. However, little is 
known about recent trends in their occurrence, their association with serum glucose 
levels, and their psychological impact in ACS setting. 
Methods: We examined 25-year (1986-2011) trends in the incidence rates (IRs) and 
hospital case-fatality rates (CFRs) of VAs, and the association between serum glucose 
levels and VAs in patients with an acute myocardial infarction (AMI) in the Worcester 
Heart Attack Study. Lastly, we examined the relationship between in-hospital occurrence 
of VAs and 12-month progression of depression and anxiety among hospital survivors of 
an ACS in the longitudinal TRACE-CORE study.  
Results: We found the IRs declined for several major VAs between 1986 and 2011while 
the hospital CFRs declined in both patients with and without VAs over this period. 
Elevated serum glucose levels at hospital admission were associated with a higher risk of 
developing in-hospital VAs. Occurrence of VAs, however, was not associated with 
worsening progression of symptoms of depression and/or anxiety over a 12-month 
follow-up period in patients discharged after an ACS.  
Conclusions: The burden and impact of VAs in patients with an AMI has declined over 
time. Elevated serum glucose levels at hospital admission may serve as a predictor for in-
hospital occurrence of serious cardiac arrhythmias. In-hospital occurrence of VAs may 
not be associated with worsening progression of symptoms of depression and anxiety in 
patients with an ACS.  
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CHAPTER I 
 
 
INTRODUCTION 
Ventricular arrhythmias are common complications of acute myocardial 
infarction 
Ventricular arrhythmias, including ventricular tachycardia (VT) and ventricular 
fibrillation (VF) frequently complicate the clinical course of patients hospitalized with 
acute myocardial infarction (AMI), in upwards of 25% of patients.1,2 The development of 
theses  ventricular arrhythmias (VAs) in patients with AMI is associated with a large 
infarct size, ventricular wall dyskinesis, ventricular dysfunction, and extent of underlying 
coronary artery disease.3 The incidence rates of VAs complicating AMI are higher in 
patients who develop an ST-elevation myocardial infarction (STEMI) than in those who 
develop an non-ST-elevation myocardial infarction (NSTEMI) or unstable angina. For 
instance, in the Early Glycoprotein IIb/IIIa Inhibition in non ST-elevation ACS (EARLY 
ACS) trial of 9,211 patients hospitalized with non-ST-elevation acute coronary 
syndrome, VT occurred  in 0.8% of patients4. On the other hand, in a study of 225 
patients who underwent a primary coronary intervention (PCI) for their STEMI, VT 
occurred in up to two thirds of this population.5 
The occurrence of VAs is associated with worse in-hospital and long-term 
outcomes, especially sudden cardiac death.6 Data from 16,842 patients with AMI in the 
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Gruppo Italiano per lo Studio della Soprovvivenza nell’Infarto Miocardico (GISSI-3) trial 
showed that VAs were associated with a 6-fold higher risk of death at 6 weeks post 
discharge compared with patients who did not develop VAs.7 In the Metabolic Efficiency 
With Ranolazine for Less Ischemia in Non–ST-Elevation Acute Coronary Syndrome–
Thrombolysis in Myocardial Infarction 36 (MERLIN-TIMI 36) trial of 6,560 patients 
hospitalized with a NSTE-ACS, the occurrence of VAs  was associated with a 2.3-2.8 
times higher risk of sudden cardiac death after 1 year in comparison to patients who did 
not develop VAs.  
VAs primarily occur during the first 24-48 hours after acute symptom onset in 
patients with an AMI.5 For instance, among 5,745 patients with a STEMI from 296 sites 
in 17 countries in the Assessment of Pexelizumab in Acute Myocardial Infarction (APEX 
AMI) trial, the vast majority (90%) of cases of VT or VF occurred within 48 hours of 
symptom onset.8 In patients with a STEMI, early (within 48 hours after symptom onset) 
VT has been associated with a higher in-hospital and 30-day death rate but not worse 
long-term outcomes, whereas late (after the first 48 hours) VT usually is associated with 
worse in-hospital and long-term outcomes.9-11 On the other hand, prior studies have 
shown that both early and late VAs have been associated with worse long-term outcomes 
in patients with an NSTEMI. For example, in the EARLY ACS trial, both early and  late 
VT was associated with a higher risk of 30-day and 1-year all-cause mortality compared 
to patients who did not develop VT.12 
Recent trends in ventricular arrhythmias complicating acute myocardial 
infarction 
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National data on either the incidence rates (IRs) or case-fatality rates (CFRs) of 
VAs complicating AMI in the U.S. are not available. In a medical records linkage study 
of 2,317 patients who were admitted to all hospitals in Olmsted county, Minnesota, for an 
acute or old MI or angina pectoris, the annual incidence rate of sustained VT remained 
stable at 1.8% while that of VF decreased from 7.7% in 1979 to 5.0% in 1998.13 
However, more recent trends in the IRs and CFRs of VAs complicating AMI in the U.S. 
have not been examined. Nevertheless, several changes in the management of AMI 
during recent years, including the prompt administration of percutaneous coronary 
intervention (PCI), or the early use of beta-blockers, may have led to a change in the 
magnitude and/or short-term outcomes of VT and VF after AMI.14,15 More important, 
changes in treatment practices, include aggressive reperfusion therapies, may affect 
patients with a STEMI differently from patients with a NSTEMI. Thus, reexamination of 
potentially changing trends in the incidence and CFRs of VT complicating AMI during 
recent years is needed to understand the contemporary burden of these serious 
complications. 
Mechanisms underlying the development of ventricular arrhythmias in acute 
myocardial infarction 
The underlying electrophysiological mechanisms of VAs in the setting of AMI 
are multifactorial and complex, involving substrate, trigger, and modulating factors, each 
of which depend on the time course of myocardial ischemia.16 In the very early phase 
(within 4 hours) of an acute coronary event, the increase in resting membrane potential, 
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reduction in action potential amplitude, upstroke velocity and duration, and early cellular 
uncoupling17, re-entry within the ischemic myocardium, and reperfusion injury18 
contribute to the onset of VAs. In the subacute phase (between 4 hours and 72 hours) of 
the acute coronary event, VT is provoked by increased automaticity in surviving Purkinje 
cells which give rise to reentry and triggered activity.16 In later stages, VT usually occurs 
due to reentry pathways that occur via isolated bundles of surviving myocytes at the 
border of the infarct and the larger sub-endocardial muscle mass.19  
Several systemic changes in response to a myocardial injury are thought to 
contribute to electrophysiological disturbances that lead the development of VAs. The 
activation of sympathetic system plays an important role in the development of VAs, 
especially in very early and early phases.17 Studies in animal models found 
catecholamines were released within 10 minutes from myocardial ischemia and was 
correlated with the ischemic duration.20 Ischemia-induced catecholamine release is 
suggested to mediate occurrence of VAs.21 Other studies also suggest that systemic 
inflammation, demonstrated by an elevation in C-reactive protein or leukocytes levels, 
may also contribute to the development of VAs.22,23 Although these proposed mediating 
factors are in accordant with severer clinical presentation observed in patients who 
develop VAs, the evidence on these factors are still contradicting, perhaps due to the 
complex and multifactorial nature of these arrhythmic complications.17,24  
Factors associated with the occurrence of ventricular arrhythmias 
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To better identify, monitor, and treat patients at higher risk of developing VAs 
during hospitalization for an AMI, several studies have examined factors associated with 
developing of VAs . Several factors, including younger age25, female sex, lower systolic 
blood pressure or higher heart rate26, higher Killip class27, atrial fibrillation13, heart 
failure, cardiogenic shock, chronic kidney disease, and presentation within 6 hours of 
acute symptoms28 have been found to be associated with VAs. Data from more than 
26,000 patients with NSTE ACS in the Global Use of Streptokinase and tPA for 
Occluded Arteries (GUSTO)-IIb, Platelet Glycoprotein IIb/IIIa in Unstable Angina: 
Receptor Suppression Using Integrilin Therapy (PURSUIT), Platelet IIb/IIIa Antagonism 
for the Reduction of Acute Coronary Syndrome Events in a Global Organization Network 
(PARAGON)-A, and PARAGON-B trials showed that chronic obstructive pulmonary 
disease, prior myocardial infarction, and ST-segment changes at presentation were 
associated with the in-hospital development of VAs.6  
On electrocardiography, a QTc dispersion, or premature beat with early coupling 
(R on T phenomenon) has been suggested to be associated with higher odds of 
developing VAs after an AMI29-32; however, evidence is mixed33-35. Electrolyte 
abnormalities, such as hypokalemia at the time of hospital admission, has also been 
associated with the occurrence of VAs.36 Early successful restoration of coronary flow 
with fibrinolysis or PCI has been shown to reduce the risk of VAs.37,38 In the APEX AMI 
trial, Killip class greater than I, baseline systolic blood pressure, baseline heart rate 
greater than 70 beat/minute, pre-PCI and post-PCI TIMI flow grade 0 were associated 
with occurrence of VAs.8. However, the role of several markers for inflammation or the 
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stress response early during the course of AMI (e.g., white blood cell count, C-Reactive 
Protein (CRP), or serum glucose levels) on the development of VAs have not been well 
studied. These factors, which have also been found to be associated with a more 
extensive infarction and worse short-term outcomes, may be related to the development 
of this arrhythmic complication. 
A limited number of studies have suggested that risk factors for early or late VAs 
may be different as may be their mechanisms. For example, an anterior infarction has 
been shown to be associated with the development of early VAs, whereas an inferior 
infarction has been shown to be associated with VAs occurring at a later time.39 In 
addition, these factors may be different in patients who have a STEMI as with patients 
who suffer an NSTEMI, or in patients who receive different reperfusion treatment 
strategies since the underlying mechanism may be different in each of these particular 
patient subgroups. Thus, understanding regarding factors associated with VAs must also 
examine potential variation in subgroups of patients.  
Potential association between serum glucose levels and ventricular 
arrhythmias 
Early after the onset of an AMI, the sympathetic nervous system responds to 
physiological and emotional stress with the release of noradrenalin.40 Serum glucose 
levels typically increase early after an AMI in 25-50% of patients, reflecting a preexisting 
insulin resistance or an acute response to physiological/emotional stress after the acute 
coronary event.40,41 Elevated serum glucose levels at the time of hospital admission have 
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been associated  with worse outcomes in the setting of AMI, including in-hospital and 
long-term death in both diabetic and nondiabetic patients42.43,44 
The hyperglycemic state can directly alter cardiac electrophysiological status, 
creating  conditions that facilitate the occurrence of VAs.42 In addition, hyperglycemia is 
associated with more extensive infarct size,45 impaired microvascular circulation,46 and 
worse left ventricular function,47 each of which can promote electrical instability. 
However, few studies have examined the association between serum glucose levels at the 
time of hospital admission and onset of VAs after an AMI. In a study of 1,258 patients 
with AMI, a glucose level of >180 mg/dl at admission was associated with a higher risk 
of developing VAs or ventricular fibrillation after adjusting for several potentially 
confounding factors.48 In a small study among 76 diabetic patients with a first AMI, 
serum glucose levels  >225 mg/dl were associated with several myocardial electrical 
complications, including Vas, ventricular premature complex, atrial fibrillation, and 
conduction system disorders.49 However, these studies have considered VAs together 
with other arrhythmias, which may not share the same underlying mechanisms, and 
ignored the timeline of VAs onset from the beginning of acute coronary related 
symptoms. Inasmuch, there is a need to reexamine the association between serum glucose 
levels at the time of hospital admission with the occurrence of VAs in a large sample of 
patients hospitalized with AMI. 
Potential association between ventricular arrhythmias and depression and 
anxiety following an acute coronary syndrome  
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In patients who are diagnosed with an acute coronary syndrome (ACS), 
depression and anxiety are prevalent in up to 20-40%, approximately 10 times that of 
general population.50-53 Of importance for long-term patient management, both 
depression and anxiety are usually not transient after the ACS event, but rather long-
lasting.54,55 For instance, in the Depression after Myocardial Infarction (DepreMI) study 
of 475 patients admitted to 4 hospitals in the Netherlands for an AMI, the prevalence of 
depression was approximately 25% during the 12 month follow up period. The presence 
of depression or anxiety further complicated the in-hospital and long-term management 
of patients with an ACS,52,56,57 and untreated depression and anxiety has been associated 
with worse clinical outcomes among patients discharged from the hospital after an ACS, 
including higher all-cause death rates58,59, recurrent coronary events, and impaired quality 
or life.51,60,61 However, these conditions are often under and/or undiagnosed and under-
treated in patients hospitalized for an ACS, and have been called for greater recognition 
and attention by the American Heart Association (AHA).62 
On the other hand, the occurrence of VAs may increase the levels and frequency 
of symptoms of anxiety or depression. The symptoms of VAs, including pre-syncope 
(pounding or racing heartbeat, lightheadedness, feeling faint)2,63 or actual syncope or 
cardiac arrest can lead to further stress and fear in patients with underlying CAD, which 
may worsen the symptoms of depression or anxiety. Thus, there is a need to study the 
impact of VAs on long-term progression of depression and anxiety among patients 
surviving an ACS. However, no study has investigated the association between 
occurrence of VAs and trajectories of depression or anxiety following an ACS.  
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Study aims and hypotheses 
The discussion in this thesis is intended to fill the current gaps in the knowledge 
of VAs in the setting of an ACS by archiving the following aims. 
Aim 1:  
Examine 25 year trends (1986-2011) in the incidence rates and compare the in-
hospital case-fatality rates of patients who developed, versus those who did not develop 
VAs complicating AMI in the Worcester Heart Attach Study (WHAS) 
Hypothesis: The incidence rates and case-fatality rates of VAs (including VT and 
VF) decreased during the period under study with larger declines observed among 
patients with STEMI than in patients with NSTEMI. 
Aim 2: 
Examine the association between serum glucose levels at hospital admission with 
in-hospital occurrence of VAs using data from the WHAS. 
Hypothesis: Patients who had higher levels of serum glucose were more likely to 
develop VAs during the hospitalization for an AMI. 
Aim 3: 
Examine association between occurrence of VAs and progression of depressive 
and anxiety symptoms over a 12-month period in patients discharged from the hospital 
after an acute coronary syndrome (ACS) in the Transitions, Risks, and Action in 
Coronary Events – Center for Outcomes Research and Education (TRACE-CORE) study. 
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Hypothesis: Patients who experienced in-hospital VAs had higher risk of 
developing depression or anxiety during the 12-month period following hospital 
discharge for an ACS compared with patients who did not develop VAs.  
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CHAPTER II 
 
 
TWENTY-FIVE YEAR TRENDS (1986-2011) IN HOSPITAL INCIDENCE AND 
CASE-FATALITY RATES OF VENTRICULAR ARRHYTHMIAS AND 
FIBRILLATION COMPLICATING ACUTE MYOCARDIAL INFARCTION 
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Abstract 
Background:  Long-term trends in the incidence rates (IRs) and hospital case-fatality rates 
(CFRs) of ventricular tachycardia (VT) and ventricular fibrillation (VF) among patients 
hospitalized with acute myocardial infarction (AMI) have not been recently examined. 
Methods: We used data from 11,825 patients hospitalized with AMI at all 11 medical centers in 
central Massachusetts on a biennial basis between 1986 and 2011. Multivariable logistic 
regression modeling was used to examine trends in hospital IRs and CFRs of VT and VF 
complicating AMI. 
Results: The median age of study population was 71 years; 57.9% was male, and 94.7% 
was white. The hospital IRs declined from 14.3% in 1986/1988 to 10.5% in 2009/2011 
for VT and from 8.2% to 1.7% for VF. Over the same period, in-hospital CFRs declined 
from 27.7% to 6.9% for VT and from 49.6% to 36.0% for VF. The IRs of both early (<48 
hours) and late VT and VF declined over time, with greater declines in those of late VT 
and VF. The incidence of VT declined similarly for patients with either type of AMI, 
while for VF it declined only in those with a STEMI.  
Conclusion: The hospital incidence and mortality rates of VT and VF have declined over time, 
likely due to changes in acute monitoring and treatment practices. Despite these encouraging 
trends, efforts remain needed to identify patients at risk for these serious ventricular arrhythmias 
and implement preventive and treatment strategies as necessary.  
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Introduction 
Ventricular tachycardia (VT) and ventricular fibrillation (VF) frequently 
complicate the clinical course of patients hospitalized with an acute myocardial 
infarction.1,2 The development of these serious ventricular arrhythmias in patients 
hospitalized with an acute myocardial infarction (AMI) is often associated with a larger 
infarct, ventricular wall dyskinesia and dysfunction, more extensive underlying coronary 
artery disease, and ST segment-elevation myocardial infarction (STEMI).3-5,8 The 
development of VT and VF in patients hospitalized with AMI is associated with 
increased in-hospital and post discharge morbidity and mortality.6,7 
National data on either the incidence rates (IRs) or case-fatality rates (CFRs) of 
VT and VF complicating AMI in the U.S. are not presently available. In a medical 
records linkage study of 2,280 patients who were admitted to all hospitals in Olmsted 
County, Minnesota, for coronary heart disease between 1979 and 1998, the annual IRs of 
sustained VT remained stable at 1.8%, while the IRs of VF declined from 7.7% in the 
initial study years to 5.0% during the most recent years under study.13 However, this 
study was limited by its small sample size and by the lack of more contemporary data. A 
number of changes in the more optimal management of patients hospitalized with acute 
coronary disease during recent years may have led to favorable changes in the magnitude 
and/or outcomes of ventricular arrhythmias among patients hospitalized for an AMI.14,15  
Using data from a population-based surveillance study of patients hospitalized 
with confirmed AMI at all central Massachusetts medical centers, we examined 25-year 
trends (1986-2011) in the hospital IRs and CFRs of VT and VF, and compared 
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differences in the in-hospital CFRs of patients who developed, with those who did not 
develop, VT or VF complicating their AMI. 
Methods 
Study design and data collection 
Data from the Worcester Heart Attack Study (WHAS), an ongoing population-
based investigation that is examining long-term trends in the incidence, in hospital, and 
post-discharge CFRs of AMI among residents of the Worcester, Massachusetts, 
metropolitan area were used for this investigation. The details of this study have been 
described previously.64-69 In brief, the medical records of residents of central 
Massachusetts hospitalized for possible AMI at the 11 medical centers serving residents 
of this large central New England metropolitan area were individually reviewed. The 
diagnosis of AMI was independently validated according to criteria developed by the 
World Health Organization with further sub-classification into those with an ST-segment 
elevation AMI (STEMI) or Non-ST segment elevation AMI (NSTEMI).70,71 This 
investigation was approved by the Institutional Review Board at the University of 
Massachusetts Medical School. 
Trained nurses and physicians abstracted demographic and clinical data from the 
medical records of residents of the Worcester metropolitan area hospitalized with a 
confirmed AMI. Quality control activities were routinely conducted on all nurse and 
physician data abstractors. Abstracted information included patient’s age, sex, medical 
history, physiologic factors, laboratory test results at the time of hospital admission, and 
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length of hospital stay. Information about the in-hospital use of important cardiac 
medications, coronary angiography, percutaneous coronary intervention (PCI), and 
coronary artery bypass graft (CABG) surgery was collected. Development of several 
significant clinical complications (e.g., atrial fibrillation, cardiogenic shock, stroke, heart 
failure, survival status) during the patient’s index hospitalization was defined according 
to standardized criteria.71-74 
Study population 
Among the 12,804 residents of the Worcester metropolitan area who were 
hospitalized with an independently verified AMI on an approximate biennial basis 
between 1986 and 2011, we excluded patients with missing data on age (n=281), race 
(n=476), serum potassium levels (n=212), and length of hospital stay (n=10). The final 
study sample consisted of 11,825 patients with an AMI. 
Ventricular arrhythmias  
In the present study, the occurrence of VT and VF was based on physicians’ 
progress notes. To reduce the possible misclassification of VT and VF due to 
underreported occurrence of these arrhythmias in physicians’ notes, the study research 
physicians also reviewed patients’ ECG strips in their hospital medical records. 
Ventricular tachycardia was defined as a cardiac arrhythmia of three or more consecutive 
complexes originating in the ventricles at a rate of greater than 100 beats per minute 
(cycle length less than 600 milliseconds).2 Information was also collected about the date 
of initial VT occurrence since hospital admission. Ventricular fibrillation was defined as 
a rapid, usually more than 300 beats per minute (cycle length 200 millisecond or less), 
16 
 
 
grossly irregular ventricular rhythm with marked variability in QRS cycle length, 
morphology, and amplitude.2 
Following definitions used in prior investigations,13,68,75 we further classified VT 
and VF as either occurring early (within 48 hours after hospital admission) or late (after 
the first 48 hours) and primary (occurring without concomitant heart failure or 
cardiogenic shock) or secondary to concurrent heart failure or cardiogenic shock. For 
patients who had multiple episodes of VT (582/1,731 patients, 33.6%) and VF (158/574 
patients, 27.5%), only the first episode was counted. We classified the 348 patients who 
developed both VT and VF as having VF, since VF is more clinically serious than VT.  
Statistical analysis 
Patient characteristics, including demographic factors, clinical presentation, 
physiologic findings, and laboratory test results were compared between patients who 
developed VT or VF, and those who did not, using Chi-Square tests for categorical 
variables and the t-test or Kruskal–Wallis test for continuous variables. Changes in these 
characteristics between our respective comparison groups were also examined across 
study years using chi square tests for trends.  
The hospital IRs (e.g., frequencies) of VT and VF complicating AMI were 
calculated as the proportion of new cases of VT and VF which occurred among all 
patients hospitalized with AMI.75 In-hospital CFRs for each condition were calculated as 
the number of in-hospital deaths/total number of cases with a particular arrhythmia.76 The 
IRs and CFRs were graphed on continuous admission date between 1986 and 2011 using 
locally weighted line least-square smoothing.77 
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We controlled for the effects of changes in patients’ demographic characteristics, 
clinical presentation, and medical therapies and reperfusion practices on trends in hospital 
IRs and CFRs using multivariable logistic regression modelling. Study year was treated 
as an integer-valued variable when examining linear trends in these endpoints. Potentially 
confounding factors were identified based on differences in the baseline characteristics of 
hospitalized patients according to the presence or absence of VT or VF using a p-value of 
<0.05 as a cutoff. These variables were successively introduced into the multivariable 
logistic regression model in blocks to a full model. Since length of hospital stay may 
affect the possibility of capturing VT or VF during the patient’s acute hospitalization, or 
serve as a proxy for disease severity, length of stay was also included in the fully adjusted 
models as a potentially confounding factor.  
We also examined the overall magnitude, and changes over time therein, in the 
frequencies of VT and VF based on the presence of concomitant heart failure/cardiogenic 
shock or not. Since the occurrence of VT may differ between patients with a STEMI and 
NSTEMI, trends in the hospital IRs and CFRs of VT were also examined for these two 
groups, separately in patients admitted to all central Massachusetts hospitals between 
2001 and 2011, when information about the type of AMI was collected. We also 
examined trends in hospital IRs of early (during the first 2 days after hospital admission) 
versus late VT in patients further classified by type of AMI (e.g., STEMI vs. NSTEMI). 
Given the large size of this study, almost all differences that were observed were 
highly statistically significant. Thus, all reported differences without an explicit P-value 
had a p value <0.05.  
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Results 
Baseline patient characteristics  
The median age of the study population was 71 years, most patients were white 
(94.7%), and 57.9% were men. Patients whose clinical course was complicated by either 
VT (n=1,731) or VF (n=574) were several years younger than patients who did not 
develop these serious ventricular arrhythmias and were more likely to be male (Table 
2.1). Patients who developed VT or VF were less likely to have a medical history of 
diabetes, hypertension, or a stroke/transient ischemic attack. On the other hand, patients 
in whom these arrhythmias were diagnosed were more likely to have developed 
important clinical complications (e.g., atrial fibrillation, heart failure, cardiogenic shock) 
during their acute hospitalization. Compared with patients who did not develop these 
ventricular arrhythmias, patients who developed VT or VF were more likely to have been 
treated with antiarrhythmic agents or thrombolytic therapy, but less likely to have 
received aspirin, Angiotensin converting enzyme inhibitor/Angiotensin II receptor 
blockers (ACE-I/ARBs), beta blockers, and lipid lowering agents.  
Between 1986 and 2011, the prevalence of several preexisting comorbidities (e.g., 
heart failure, diabetes, hypertension, stroke) increased (Table 2.2), as did the prescribing 
of aspirin, ACE-I/ARBs, beta blockers, lipid lowering agents, PCI, and CABG surgery. 
During this period, there were declines in the frequency of several important in-hospital 
complications, including atrial fibrillation, heart failure, and cardiogenic shock. Receipt 
of thrombolytic therapy and the average hospital length of stay also decreased (Table 
2.2). 
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Twenty-five year trends in hospital IRs of VT and VF  
Between 1986 and 2011, VT developed in 14.6% and VF in 4.9% of all patients 
admitted to central Massachusetts hospitals for an AMI. During this period, the 
proportion of patients with AMI who developed VT declined from 14.3% in 1986/1988 
to 10.5% in 2009/2011 while the proportion of patients who developed VF declined from 
8.2% in 1986/1988 to 1.7% in 2009/2011 (Figure 2.1, top panel). After adjusting for 
changes in the demographic and clinical characteristics of our patient population over 
time, the proportion of patients who developed VT declined by approximately 11% 
(95%CI=6-17%) while the proportion of patients who developed VF declined by 37% 
(95%CI=30-43%) after each decade, respectively (Table 2.3). After we adjusted for 
changes over time in the receipt of various cardiac medications and reperfusion therapies 
received at the time of hospital admission during the years under study, the proportion of 
patients who developed VT did not change over time while adjustment for the receipt of 
these therapies attenuated the magnitude of the decline in IRs of VF after each decade to 
20% (95%CI=7-32%).  
Trends in hospital IRs of VT and VF according to concomitant heart failure or 
cardiogenic shock 
Approximately 41% of our 11,825 study patients developed either heart failure or 
cardiogenic shock during their hospitalization for AMI. The development of ventricular 
arrhythmias in these patients was more common than in patients who did not develop 
either heart failure or cardiogenic shock (17.2% vs. 12.9% for VT and 7.3% vs. 3.2% for 
VF, respectively). The proportion of patients who developed VT among those with 
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concomitant heart failure or cardiogenic shock decreased from 17.7% in 1986/1988 to 
13.6% in 2009/2011 while the hospital IRs for VT for those who did not develop these 
hemodynamic disturbances did not significantly decline (p=0.45). The IRs of VF among 
those with concomitant heart failure or cardiogenic shock decreased from 10.7% in 
1986/1988 to 2.1% in 2009/2011 compared with a decrease from 6.0% in 1986/1988 to 
1.6% in 2009/2011 among patients without concomitant heart failure or cardiogenic 
shock (Figure 2.1, bottom panel). 
Trends in hospital IRs of ventricular arrhythmias by timing of occurrence   
Data on the time of occurrence of VT and VF and type of AMI were collected in 
5,764 patients admitted to all greater Worcester hospitals on a biennial basis with AMI 
between 2001 and 2011. During this period, VT occurred in 13.2% while VF occurred in 
2.8% of these patients, respectively. The frequency of VT declined from 15.8% in 
2001/2003 to 9.9% in 2009/2011 and from 3.5% to 1.6% for VF. More than two thirds of 
all VT and VF episodes occurred during the first 48 hours after hospital admission. The 
hospital IRs of both early and late VT declined over time, with greater declines noted for 
those with late VT in both relative and absolute terms (Figure 2, top panel). Similarly, the 
incidence rates of early and late VF significantly declined during the most recent decade 
under study, with a larger decline observed for late VF (Figure 2.2). 
Trends in hospital IRs of ventricular arrhythmias according to type of AMI  
During the most recent decade (2001-2011) under study in which data were 
collected on the type of AMI patients experienced, 32.0% of study patients (n=1,161) 
were diagnosed with a STEMI. The occurrence of both VT and VF were more common 
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in patients with a STEMI than for those with an NSTEMI (17.3% vs. 11.3% for VT and 
5.3% versus 1.6% for VF). Among patients with a STEMI, about 80% of episodes of VT 
and VF occurred within the first 48 hours after hospital admission, compared with only 
60% of such episodes for those with an NSTEMI. The hospital IRs of VT and VF 
declined between 2001 and 2011 in patients with a STEMI (Figure 2.2, bottom panel). 
The IRs of VT also declined in patients with an NSTEMI, whereas the IRs of VF in these 
patients did not change significantly over time (p=0.25, Figure 2.2).  
Twenty-five year trends in Hospital CFRs of VT and VF  
The overall in-hospital CFRs were 48.3% among patients who developed VF, 
13.9% in patients who developed VT, and 8.9% in patients who did not develop either of 
these ventricular arrhythmias during their acute hospital stay. The in-hospital CFRs 
decreased from 27.7% in our 2 initial study years (1986/1988) to 6.9% in our 2 most 
recent study years of 2009/2011 for patients who developed VT, from 49.6% to 36.0% 
for patients who developed VF, and from 11.5% to 4.6%for those whose hospital course 
was not complicated by either VT or VF (Figure 2.3). After adjusting for changes in 
patient’s demographic characteristics and clinical presentation during the years under 
study, the hospital CFRs decreased by 41% (95%CI=39-50%) for patients who developed 
VT and by 24% (95%CI=14-32%) for those who developed VF after each study decade 
(Table 2.3). However, the declining trends in the hospital CFRs of VT and VF were 
markedly attenuated after adjusting for the receipt of various cardiac medications and 
reperfusion treatments during the patient’s index hospitalization. 
Discussion  
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In this community-based study of approximately twelve thousand patients 
hospitalized with AMI at all central Massachusetts medical centers, we found that the 
incidence rates of both VT and VF, especially among patients with concomitant heart 
failure or cardiogenic shock, declined between 1986 and 2011. While the in-hospital 
death rates for patients whose hospital course was complicated by VT or VF have 
declined during the study period, mortality remained high, at approximately 40% in 
patients who developed VF in 2009/2011. Between 2001 and 2011, trends in the 
magnitude of early vs. late VT differed, while trends in the frequency of VF complicating 
AMI differed according to the type of AMI patients developed. 
Trends in the hospital incidence rates of VT complicating AMI  
We observed declining trends in the frequency of sustained and nonsustained VT 
among patients admitted to the hospital for an AMI between 1986 and 2011. Published 
data examining long-term or recent trends in the magnitude or death rates associated with 
VT complicating AMI are extremely limited. In a study of 2,280 patients who were 
admitted to all hospitals in Olmsted County, Minnesota, for an AMI between 1979 and 
1998, sustained VT occurred in 1.8% of hospitalized patients.13  
Notably, our observed declines in the frequency of VT were primarily driven by 
declines in VT among patients who had concomitant heart failure or cardiogenic shock. 
The declines we observed in the frequency of VT in patients with heart failure or 
cardiogenic shock might be due to increases in the use of coronary reperfusion therapies, 
including thrombolytic therapy and PCI, which have been shown to improve cardiac 
function and lower the risk of developing heart failure.78 Indeed, in our study, the 
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proportion of patients who developed heart failure after AMI decreased from 44% in 
1986 to 29% in 2011.  
While reperfusion therapies might reduce the incidence of primary and secondary 
VT after AMI, reperfusion arrhythmias, including VT, might offset these benefits.8,79 An 
increasing occurrence of reperfusion arrhythmias might also explain the smaller decrease 
in the incidence of early VT, where reperfusion VTs are more prevalent, compared with 
the incidence rates of late VT that were observed between 2001 and 2011. 
While evidence-based treatment modalities may have an impact on preventing 
early onset VT, which is often induced by transient abnormalities of automaticity or 
triggered activity following acute myocardial ischemia, these treatments can reduce 
infarct size and remodeling of the arrhythmic substrate or reentry pathways, thereby 
reducing the risk of late VT.16 Discontinuation of the use of prophylactic lidocaine and 
other antiarrhythmic agents in the mid-1990s might also have contributed to declines in 
the frequency of VT.80,81 The trends we observed are consistent with these hypotheses; 
however, disentangling the interplay of these factors on trends in the incidence rates of 
VT is complex, and remains a research topic for further study.  
Trends in the hospital incidence rates of VF complicating AMI  
The frequency of primary VF (i.e., VF which occurs in patients without heart 
failure or cardiogenic shock) and secondary VF among patients with an AMI also 
decreased between 1986 and 2011, with a larger decrease in the frequency of secondary 
VF. This finding was in contrast to our prior analysis of data from this community-wide 
study which failed to find a significant change in the incidence rates of primary VF 
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complicating AMI between 1975 and 1997,68,69 or with the results of the Rochester 
Epidemiology study between 1979 and 1998.13   
Declining trends in the magnitude of VF that we observed may be due, in part, to 
the favorable effects of increased utilization of evidence-based treatments for AMI during 
the years under study. In contrast with relatively stable trends in the frequency of VT 
between 1986 and 2011, declines in the occurrence of primary VF might be explained by 
the fact that reperfusion-induced VF occurs in a considerably smaller proportion of 
treated patients compared with the frequency of VT.82  
Trends in hospital incidence rates of VT and VF according to type of AMI  
Consistent with prior reports,6,83,84 we found that VT and VF occurred more 
commonly in patients with a STEMI than in patients with an NSTEMI. Most instances of 
VT and VF tended to occur early within the first 48 hours of hospitalization in patients 
with a STEMI while slightly more than one half of all episodes of VF occurred during 
this high-risk period among patients with an NSTEMI. The greater frequency of 
ventricular arrhythmias in patients with a STEMI is possibly due to the more common 
occurrence of electrical or inflammatory disturbances that result after the complete 
blockage of a coronary artery compared to less common disturbances due to residual 
coronary flow in patients with an NSTEMI.85 In addition, emergent PCI is more common 
in patients with a STEMI, which may result in a greater frequency of reperfusion-induced 
VT as compared to patients with an NSTEMI, where a “watchful waiting” strategy is 
more commonly employed. Differences in the timing of these ventricular arrhythmias 
may have implications for when to discharge high risk patients with an NSTEMI. 
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However, later discharge and/or increased post-discharge surveillance for patients with 
an NSTEMI needs to be considered from a cost-benefit perspective given the fairly low 
incidence rates of VF (1.6%) among these patients.  
Patients with either a STEMI or a NSTEMI experienced a decline in the hospital 
frequency of VT between 2001 and 2011. Similar trends were observed with regards to 
the development of VF among patients with an STEM while the incidence of VF among 
patients with an NSTEMI did not change. It is unclear why the frequency of VF did not 
decrease in patients with a NSTEMI during the study period. However, the low frequency 
of VF (1.6%) among these patients might have been difficult to detect in our study. 
Differences in the trends of VT and VF among patients with an NSTEMI may also 
suggest distinct underlying mechanisms and risk factors for the development of these 
serious arrhythmias among these patients.  
Trends in hospital case-fatality rates of VT and VF complicating AMI  
We observed an encouraging decline in the hospital death rates of patients who 
did not develop VT or VF, as well as in patients who developed either VT or VF, 
between 1986 and 2011. Our prior work also found a lower odds of dying among patients 
who developed primary VF in the late 1990s and early 2000s compared with the late 
1970s.75  
Improvements in the timing and use of in-hospital cardiopulmonary resuscitation 
might have contributed to the decreased in-hospital CFRs of VT and VF that we observed 
during the years under study. Data from 17,490 patients with in-hospital pulseless VT or 
VF who were studied in the Get With The Guidelines–Resuscitation registry showed that 
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immediate survival after resuscitation increased from 58% in 2001 to 72% in 2009.86 
Several factors, including early recognition and rapid defibrillation, greater availability of 
trained personnel, better chest compressions, and therapeutic hypothermia likely 
contributed to improved survival rates.86-89 For patients with hemodynamically stable VT, 
changes in patient management, including correction of electrolyte and acid/base 
abnormalities and treatment of important clinical complications during the period under 
study may have further reduced the risk of deterioration into pulseless VT or VF and 
death.  
It is important to note that in the present study, changes in medical treatments, 
namely the increased use of aspirin, ACE-I/ARBs, beta blockers, and lipid-lowering 
agents, as well as increased use of PCI and CABG surgery during the period under study, 
primarily accounted for the improvement in the short-term survival rates we observed 
among patients who developed either VT or VF. Our findings provide encouragement for 
the continued high use of effective treatments for AMI to reduce the risk of dying from 
these ventricular arrhythmias.  
Study strengths and limitations  
The present study has several strengths. It is among the very few studies that have 
provided more generalizable community-based epidemiologic data that can furnish 
insights into the magnitude and impact of the major ventricular arrhythmias in patients 
hospitalized with AMI. All patients admitted to the coronary care unit were telemonitored 
for their entire stay, making it unlikely that episodes of asymptomatic and nonsustained 
VT were missed. However, our study also has several limitations. Due to considerable 
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missing data on duration of prehospital delay, we were unable to systematically classify 
the time of onset of VT or VF according to symptom onset. However, in an analysis of 
1,501 patients with available information, the classification of early from late VT or VF 
based on acute symptom onset agreed well with that based on the timing of hospital 
admission. 
Conclusions 
The results of this community-wide study found declining multi-decade long 
trends in the incidence and mortality of VT and VF following AMI. The encouraging 
trends that we observed are likely due to changes in hospital treatment practices during 
the years under study. However, efforts remain needed to identify patients at risk for 
these serious ventricular arrhythmias and implement effective preventive and treatment 
strategies as necessary.  
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Table 0.1: Baseline characteristics of patients admitted to the hospital for an acute myocardial 
infarction according to the presence of ventricular tachycardia or ventricular fibrillation  
Characteristics 
No VT/VF 
(n= 9,520) 
VT 
(n= 1,731) 
VF  
(n= 574) 
p1 p2 
Age (median [IQR], years) 72 [60-81] 70 [58-79] 68 [58-77] <0.001 <0.001 
Age (years, %)      <0.001 <0.001 
<55 15.3 19.5 19.0   
55-64 18.3 18.9 20.4   
65-74 24.5 25.0 28.9   
≥75 42.0 36.6 31.7   
Men (%)   55.7 66.7 67.8 <0.001 <0.001 
White (%)   94.4 96.0 95.1 0.010 0.49 
History of disease (%)        
Coronary artery disease 36.5 36.1 35.2 0.75 0.53 
Heart failure 20.8 21.1 14.8 0.83 0.001 
Diabetes  32.8 27.8 23.9 <0.001 <0.001 
Hypertension  65.2 60.2 57.5 <0.001 <0.001 
Angina  21.4 20.8 17.3 0.56 0.018 
Stroke/transient ischemic attack 12.6 10.3 8.7 0.009 0.006 
Admission potassium (median [IQR], 
mmol/L) 
4.2 [3.9-4.6] 4.2 [3.8-4.6] 4.0 [3.5-4.4] 0.017 <0.001 
Length of stay (median [IQR], day) 5 [3-9] 7 [4-11] 7 [2-13] <0.001 <0.001 
In hospital complications (%)      
Atrial fibrillation  15.8 24.7 27.9 <0.001 <0.001 
Heart failure 35.7 43.9 47.6 <0.001 <0.001 
Pulmonary edema 12.4 17.0 20.7 <0.001 <0.001 
Cardiogenic shock 4.3 9.2 26.7 <0.001 <0.001 
Treatment (%)      
Aspirin  82.2 81.2 67.6 0.29 <0.001 
ACE-I/ARBs 47.4 48.6 38.0 0.33 <0.001 
Antiarrhythmic agents 12.9 27.8 40.6 <0.001 <0.001 
Beta blockers 77.0 77.9 62.5 0.41 <0.001 
Lipid lowering agents 40.3 39.3 24.6 0.40 <0.001 
Thrombolytic therapy  11.3 21.4 22.0 <0.001 <0.001 
PCI   25.6 27.7 28.1 0.06 0.19 
CABG surgery  4.6 6.9 5.8 <0.001 0.19 
VT: ventricular tachycardia, VF: ventricular fibrillation (with/without VT), IQR: interquartile range, ACE-
I/ARBs: Angiotensin converting enzyme inhibitor/Angiotensin II receptor blockers, PCI: percutaneous 
coronary intervention, CABG: coronary artery bypass graft  
p-value from Chi-square test and Fisher’s exact test for categorical variables and Wilcoxon rank-sum test 
for continuous variables; p1: no VT/VF vs. VT, p2: no VT/VF vs. VF. 
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Table 0.2: Trends in the characteristics of patients admitted to the hospital for an acute 
myocardial infarction 
Characteristics 
1986-1990 
(n=2,012) 
1997-2001 
(n=3,074) 
2007-2011 
(n=2,157) 
P for trend 
Age (median [IQR], years) 70 [60-78] 73 [61-82] 68 [57-80] 0.12 
Age (years, %)       
<55 14.0 15.5 19.8  
55-64 21.8 16.1 21.1  
65-74 30.3 22.9 22.3  
≥75 33.9 45.5 36.9  
Men (%)   60.1 57.3 61.0 0.99 
White (%)   97.6 95.4 91.7 <0.001 
History of disease (%)       
Coronary artery disease 19.1 52.4 32.0 <0.001 
Congestive heart failure 14.8 23.5 20.6 <0.001 
Diabetes  25.7 32.0 38.3 <0.001 
Hypertension  49.9 65.0 74.9 <0.001 
Stable angina 27.6 23.3 6.6 <0.001 
Stroke/transient ischemic attack 9.1 13.5 13.1 <0.001 
Admission potassium (median [IQR], 
mmol/L) 
4.1 [3.7- 4.4] 4.2 [3.9- 4.7] 4.2 [3.8- 4.6] 
<0.001 
Length of stay (median [IQR], day) 10 [7- 13] 5 [3-8] 3 [2-6] <0.001 
In hospital complications (%)     
Atrial fibrillation  19.3 16.9 17.2 0.047 
Heart failure 41.5 36.1 32.4 <0.001 
Pulmonary edema 18.3 13.3 8.2 <0.001 
Cardiogenic shock 6.9 6.3 5.1 <0.001 
Treatment (%)     
Aspirin  43.7 88.4 94.5 <0.001 
ACE-I/ARBs 8.6 54.2 72.4 <0.001 
Antiarrhythmic agents 20.3 14.6 11.1 0.11 
Beta blockers 48.4 81.1 92.6 <0.001 
Lipid lowering agents 2.9 38.2 89.2 <0.001 
Thrombolytic therapy  17.4 16.2 0.6 <0.001 
PCI   2.8 22.6 53.6 <0.001 
CABG surgery 1.7 6.6 7.5 <0.001 
Note: Years 1991-1995 and 2003-2005 were omitted for easy presentation of data.  
p-values for trend were from logistic regression for categorical variables and linear regression for 
continuous variables with study year as a linear predictor. 
IQR: interquartile range, CK: creatinine kinase, ACE-I/ARBs: Angiotensin converting enzyme 
inhibitor/Angiotensin II receptor blockers, PCI: percutaneous coronary intervention, CABG: coronary 
artery bypass graft. 
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Table 0.3: Trends in hospital incidence rates and case-fatality rates of ventricular tachycardia and 
ventricular fibrillation for each decade among patients with acute myocardial infarction 
 Ventricular tachycardia Ventricular fibrillation 
Incidence rates  N= 11,251 N= 10,094 
In years 1986/1988 14.3 8.2 
In years 2009/2011 10.5 1.7 
Trends regression models IRR 95%CI IRR 95%CI 
Unadjusted 0.85 0.81-0.91 0.57 0.51-0.64 
Demographic factors (1) 0.86 0.81-0.91 0.58  0.52-0.65 
History of disease (2) & (1) 0.87 0.82-0.92 0.60 0.53-0.67 
Clinical presentation (3) & (1), (2) 0.89 0.83-0.94 0.63 0.57-0.70 
In-hospital treatments (4) & (1), (2), (3) 0.89 0.81-0.97 0.80 0.68-0.93 
Case-fatality rates N= 1,731 N= 574 
In years 1986/1988 27.7 49.5 
In years 2009/2011 6.9 37.5 
Trends regression models IRR 95%CI IRR 95%CI 
Unadjusted 0.64 0.53-0.77 0.87 0.76-0.99 
Demographic (1) 0.59 0.49-0.71 0.84 0.74-0.95 
History of disease (2) & (1) 0.57 0.47-0.68 0.80 0.71-0.90 
Clinical presentation (3) & (1), (2) 0.59 0.50-0.71 0.76 0.67-0.86 
In-hospital treatments (4) & (1), (2), (3) 1.09 0.86-1.39 1.07 0.91-1.27 
IRR: incidence rate ratio, 95%CI: 95% Confidence interval 
Note: each block of variables was added to precedent blocks in the successive models.  
Block 1: Age, sex, race 
Block 2: History of heart failure, diabetes, hypertension, and stroke/transient ischemic attack 
Block 3: In-hospital serum potassium levels, complication of atrial fibrillation, heart failure, and 
cardiogenic shock 
Block 4: In hospital treatment of aspirin, angiotensin converting enzyme inhibitors, antiarrhythmic agents, 
beta-blockers, lipid-lowering agents, thrombolytics, percutaneous coronary intervention, and coronary 
artery bypass surgery.   
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Figure 0.1: Trends in hospital incidence rates of ventricular tachycardia (VT) and ventricular 
fibrillation (VF) in patients with acute myocardial infarction, Worcester Heart Attack Study.  
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Figure 0.2: Trends in hospital incidence rates of ventricular tachycardia (VT) and ventricular 
fibrillation (VF) in patients with ST segment-elevation myocardial infarction and non-ST 
segment -elevation myocardial infarction (top panel) and by timing of VT and VF (early: in the 
first 48 hours of hospital stay, late: after the first 48 hours of hospital stay, bottom panel). 
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Figure 0.3: Trends in hospital case-fatality rates of ventricular tachycardia (VT) and 
ventricular fibrillation (VF) in patients with acute myocardial infarction, Worcester Heart 
Attack Study.  
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CHAPTER III 
 
 
ASSOCIATION BETWEEN GLYCEMIC STATE AT THE TIME OF HOSPITAL 
ADMISSION AND OCCURRENCE OF VENTRICULAR ARRHYTHMIAS IN 
PATIENTS SUFFERING ACUTE MYOCARDIAL INFARCTION 
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Abstract 
Background: While patients with hyperglycemia are at increased risk for dying in the setting of 
acute myocardial infarction (AMI), little is known about the association of hyperglycemia with 
the development of dangerous ventricular arrhythmias in patients hospitalized with AMI. 
Methods: We used data from a population-based study of patients hospitalized with AMI at all 
central Massachusetts medical centers on a biennial basis between 2001 and 2011. 
Hyperglycemia was defined as a serum glucose level ≥140mg/dl at the time of hospital 
admission. Ventricular tachycardia (VT) and fibrillation (VF) were identified from physicians’ 
progress notes and electrocardiographic findings. Multivariable logistic regression models were 
used to adjust for several potentially confounding variables.  
Results: The mean age of the study population (n=4,140) was 70 years, 58.0% were men, and 
92.7% were non-Hispanic white. Hyperglycemia was present in 51.9% of patients at the time of 
hospital admission; VT occurred in 652 patients (15.8%) and VF in 108 patients (2.6%), and two-
thirds of these episodes occurred during the first 48 hours after hospital admission (early). After 
multivariable adjustment, hyperglycemia was associated with an increased risk of VT (adjusted 
OR=1.48, 95%CI=1.23-1.78). Hyperglycemia was significantly associated with early VT 
(multivariable adjusted OR=1.39, 95%CI=1.11-1.73) but not with late VT (adjusted OR=1.19, 
95%CI=0.89-1.59). Similar associations were observed in both diabetic and nondiabetic patients, 
and in patients with and without ST-segment elevation AMI. Hyperglycemia was initially  
associated with occurrence of any VF (crude OR=1.73, 95%CI=1.16-2.59) but was not significant 
after multivariable adjustment (OR=1.44, 95%CI=0.92-2.25). 
Conclusions: Efforts should be made to closely monitor and treat hyperglycemia, especially early 
after hospital admission, in patients hospitalized for AMI to reduce their risk of VT.  
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Introduction 
Ventricular tachycardia and fibrillation frequently complicate the clinical course 
of patients hospitalized with acute myocardial infarction and is associated with worse in-
hospital and long-term outcomes, especially sudden cardiac death.6,7 The development of 
ventricular tachycardia (VT) in patients with an acute myocardial infarction (AMI) is 
typically associated with a larger infarct, ST segment elevation, ventricular dysfunction, 
and more extensive underlying coronary artery disease.4,5  
During the early stages of AMI, the sympathetic nervous system responds to 
physiological and emotional stress by releasing noradrenalin, and serum glucose levels 
typically increase shortly in response to this sympathetic stimulation.40 The 
hyperglycemic state can directly alter cardiac electrophysiological status by prolonging 
the QT-interval, thereby increasing the risk of VT and other serious cardiac 
arrhythmias.42 In addition, hyperglycemia is associated with a larger infarct size,45 
impaired microvascular circulation,46 and worse left ventricular function,47 which can 
independently promote electrical instability. Few studies have, however, examined the 
association between serum glucose levels at the time of hospital admission and 
occurrence of VT or VF after an AMI.48,90,91. Moreover, these studies have been limited 
by their small sample size, have examined the occurrence of VT with other cardiac 
arrhythmias which may not share the same underlying mechanisms, or have not 
examined the time of onset of VT in relation to elevated blood glucose levels.48,49,90,91  
Using data from a large population-based surveillance study of patients 
hospitalized with independently confirmed AMI at all 11 central Massachusetts medical 
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centers, we examined the association between serum glucose levels at the time of hospital 
admission and the development of VT and VF during the patient’s acute hospitalization. 
Methods 
Study design and data collection 
We used data from the Worcester Heart Attack Study, an ongoing population-
based investigation that is examining long-term trends in the incidence, hospital, and 
post-discharge case-fatality rates of AMI among residents of the Worcester, 
Massachusetts, metropolitan area for this investigation.65 In brief, the medical records of 
people hospitalized for possible AMI at the 11 medical centers serving residents of 
central Massachusetts were individually reviewed and the diagnosis of AMI was 
independently validated according to criteria developed by the World Health 
Organization; patients were further classified into those with an ST-segment elevation 
AMI (STEMI) or Non-ST segment elevation AMI (NSTEMI).70 This investigation was 
approved by the Institutional Review Board at the University of Massachusetts Medical 
School. 
Trained nurses and physicians abstracted demographic, clinical, and treatment 
data from the medical records of patients hospitalized with a confirmed AMI.65 Quality 
control was routinely conducted with all nurse and physician data abstractors. Abstracted 
information included: patient’s age, sex, medical history, physiologic factors, laboratory 
test results at the time of hospital admission, length of hospital stay, and the in-hospital 
use of important cardiac medications and procedures (coronary angiography, 
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percutaneous coronary intervention (PCI), and coronary artery bypass graft (CABG) 
surgery). Development of several significant clinical complications (e.g., atrial 
fibrillation, cardiogenic shock, stroke, heart failure) during the patient’s index 
hospitalization was identified using standardized criteria.72 
Ventricular arrhythmias  
In the present study, the occurrence of VT and VF was based on physicians’ 
progress notes. To reduce the possible misclassification of VT and VF due to 
underreported occurrence of these arrhythmias in physicians’ notes, the study research 
physicians also reviewed patients’ ECG strips in their hospital medical records. 
Ventricular tachycardia was defined as a cardiac arrhythmia of three or more consecutive 
complexes originating in the ventricles at a rate of greater than 100 beats per minute 
(cycle length less than 600 milliseconds).2 Information was also collected about the date 
of initial VT occurrence since hospital admission. Ventricular fibrillation was defined as 
a rapid, usually more than 300 beats per minute (cycle length 200 millisecond or less), 
grossly irregular ventricular rhythm with marked variability in QRS cycle length, 
morphology, and amplitude.2 
Patients were classified as having either early, defined as occurring within 48 
hours after hospital admission, or late (occurring after 48 hours) VT. For patients who 
had multiple episodes of VT and VF, only the first episode was counted.  
Serum glucose levels 
Glucose levels were measured from blood samples drawn at the time of admission 
to the emergency department of all participating medical centers as part of their standard 
40 
 
 
workup of hospitalized patients. All blood tests followed a standardized protocol in the 
laboratories at each participating hospital.  
Prior studies that have examined the prognostic impact of admission serum 
glucose levels have used various thresholds to define hyperglycemia.92,93 For purposes of 
this study, we defined hyperglycemia as a serum glucose level ≥140 mg/dl, the cutoff 
suggested by the American Heart Association (AHA) for both diabetic and nondiabetic 
patients.41 
Study population 
There was a total of 5,783 patients hospitalized with a verified AMI at all central 
Massachusetts medical centers on a biennial basis between 2001 and 2011. We excluded 
from this pool of patients 84 patients who developed VT and VF prior to hospital 
admission and 18 for whom the timing of VT or VF could not be determined. We also 
excluded patients with missing data on age (n=263), race (n=187), heart rate (n=100), 
blood pressure (n=34), serum potassium (n=42), glucose (n=87), white blood cell count 
(n=20), troponin I (n=349), and serum calcium (n=450) findings, as well as length of 
hospital stay (n=9). The final study sample consisted of 4,140 patients with 
independently confirmed AMI.  
Data Analysis 
The baseline characteristics of patients who had serum glucose levels greater or 
less than 140mg/dl were compared using Chi-Square tests for categorical variables and 
the t-test or Kruskal–Wallis test for continuous variables. We used multivariable logistic 
regression modelling to examine the association between serum glucose levels at the time 
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of hospital admission with the occurrence of VT and VF, while controlling for several 
potentially confounding factors. We a priori controlled for age, sex, and race in all 
regression models. Other variables were then iteratively tested and variables which 
changed the estimates of the effects of elevated serum glucose levels on the development 
of VT or VF by more than 10% were retained in the final models. We also carried out 
subgroup analyses in which we examined the association between hyperglycemia and VT 
and VF in patients with STEMI in comparison to those with an NSTEMI, and according 
to a history of diabetes as recorded in hospital medical records. Finally, in a sensitivity 
analysis, we used a higher serum glucose cutoff of ≥180mg/dl to define hyperglycemia to 
facilitate comparisons with a prior study.48 
Results 
Baseline patient characteristics 
The average age of the study population was 70 (± 13.8) years, 58.0% were men, 
and 92.7% were non-Hispanic whites. The mean and median [inter quartile range (IQR)] 
serum glucose levels at the time of hospital admission were 171.4 mg/dl and 143.0 
[116.0-203.0] mg/dl, respectively. Hyperglycemia, defined as a serum glucose level 
≥140mg/dl at the time of hospital admission, was present in 51.9% of hospitalized 
patients (Figure 3.1).  
Patients with high serum glucose levels at admission were approximately 5 years 
older and more likely to be female than patients with glucose levels <140mg/dl (Table 
3.1). Patients with hyperglycemia were more likely to have been previously diagnosed 
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with several important comorbidities (e.g., heart failure, chronic lung disease, chronic 
kidney disease, diabetes, and hypertension); these patients also had higher heart rate, 
serum potassium, and serum white blood cell count findings at hospital presentation than 
patients with glucose levels <140mg/dl (Table 3.1). They were also more likely to have 
developed clinically significant in-hospital complications (e.g., acute kidney injury, atrial 
fibrillation, heart failure, and cardiogenic shock) and were more likely to have received 
ACE-I/ARBs and anti-arrhythmic agents during their hospital stay compared with 
patients with lower serum glucose levels. On the other hand, patients with hyperglycemia 
had lower systolic blood pressure and serum calcium findings at hospital presentation, 
and were less likely to have received aspirin or lipid lowering agents or to have 
undergone a PCI during their acute index hospitalization.  
Serum glucose levels and incidence of ventricular tachycardia 
In our patient population, VT occurred in 652 patients (15.8%); for two-thirds of 
these patients (n=434) their first episode occurred within 48 hours of hospital admission. 
Overall, after adjusting for several demographic and clinical variables of prognostic 
importance, patients admitted with serum glucose levels ≥140mg/dl had an almost 50% 
higher odds of developing VT during their acute hospital stay than those with lower 
glucose levels (Table 3.2). This association was observed in the 434 patients who 
developed early VT (adjusted OR=1.39, 95%CI=1.11-1.73) whereas among the 218 
patients whose VT developed at a later time (more than 48 hours after hospital 
admission), the association between hyperglycemia and late onset VT was weaker and 
not statistically significant (adjusted OR=1.19, 95%CI=0.89-1.59). Adjusting for the 
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hospital receipt of various cardiac interventions and medications did not materially affect 
the observed associations.   
A history of diabetes was present in 36.1% of study patients. As expected, the 
mean and median [IQR] serum glucose levels were 224mg/dl and 209 [147-283]mg/dl 
among patients with previously diagnosed diabetes and 142mg/dl and 129 [110-
157]mg/dl among patients without a history of diabetes. However, as other have found, 
the development of VT was similar among patients with and without a history of diabetes 
(14.5% vs. 16.5%, respectively, p=0.09), and most events of VT in these patient 
populations occurred during the first 48 hours of hospital presentation (61.6% and 69.0%, 
respectively, p=0.06).  
In further examining the relationship between hyperglycemia and VT further 
stratified according to the presence of previously diagnosed diabetes, patients with 
elevated serum glucose levels had a 40-70% higher odds of developing any VT or early 
VT compared with patients with lower serum glucose levels in those with and without a 
history of diabetes (Table 3.3).  
Serum glucose levels were essentially similar for the 1,277 patients with STEMI 
and for the2,863 patients with an NSTEMI. The mean and median [IQR] serum glucose 
levels were 168mg/dl and 144 [120-189]mg/dl, respectively, in patients with a STEMI 
and 173mg/dl and 143 [114-210]mg/dl, respectively, in patients who had an NSTEMI 
(p=0.46). However, VT developed significantly more often in patients with a STEMI 
than an NSTEMI (22.0% vs. 13.0%, respectively, p<0.001) and a significantly greater 
proportion of VT episodes occurred during the first 48 hours of hospital admission in 
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patients with a STEMI (78.7%) than among those with an NSTEMI (57.4%), (p<0.001). 
Compared with patients who had lower serum glucose levels, patients who had elevated 
serum glucose levels had an approximate 30% higher multivariable adjusted odds of 
developing VT, regardless of the type of AMI (Table 3.3). 
We conducted a sensitivity analysis using a cutoff for hyperglycemia at ≥180 
mg/dl, a cut point that has been used in several prior studies.48 Using this cutoff, a total of 
1,309 patients were considered to be hyperglycemic. With this more stringent definition, 
hyperglycemia no longer was a risk factor for developing VT at any time during the 
patient’s acute hospitalization (adjusted OR=1.04, 95%CI=0.87-1.25), with essentially 
similar findings noted for the development of either early VT (adjusted OR=1.16, 
95%CI=0.90-1.49), or late VT (adjusted OR=1.09, 95%CI=0.82-1.46), nor at any time 
during the acute hospitalization for patients with a history of diabetes (adjusted OR=0.93, 
95%CI=0.69-1.25).  
Serum glucose levels and incidence of ventricular fibrillation 
Ventricular fibrillation occurred in 108 patients (2.6%), with 67 (62.0%) occurred 
within 48 hours after hospital admission. Approximately a half of patients (51.9%) who 
developed VF also developed VT. A serum glucose level ≥140mg/dl was associated with 
a higher risk of developing VF during hospitalization (OR=1.73, 95%CI=1.16-2.59). 
However, this association was attenuated and became statistically insignificant after 
adjusting for age, sex, race, history of diabetes, the development of cardiogenic shock, 
and the presence of ST-segment elevation (OR=1.44, 95%CI=0.92-2.25).  
Discussion 
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We found that patients with serum glucose levels above 140 mg/dl at the time of 
hospital admission for an AMI were at considerably greater risk for developing VT 
during their hospitalization, most notably early during their acute hospital stay, than 
patients with normoglycemia. This association was observed in both diabetic and 
nondiabetic patients and in patients with a STEMI and an NSTEMI.  
Serum glucose levels and risk of developing VT  
Elevated serum glucose levels at the time of hospital admission for AMI have 
been associated with higher death rates in both diabetic and nondiabetic patients.94 
However, evidence for an association between hyperglycemia and developing a serious 
cardiac arrhythmia, especially VT, is limited. In our large community-based study we 
found an elevated risk for developing VT among AMI patients with serum glucose levels 
≥140mg/dl. 
Our findings are consistent with those of a limited number of prior studies, despite 
their small sample sizes, non-optimal reperfusion treatment,48,90 and failure to examine 
the relation between hyperglycemia and the time of onset of VT48,91. In a study of 1,258 
consecutive patients with AMI admitted to a single coronary care unit in Valencia, Spain 
during a 4 year period, patients with serum glucose levels ≥180mg/dl at the time of 
hospital admission had more than twice the odds of developing either VT or ventricular 
fibrillation than patients with lower serum glucose levels.48 
Several mechanisms have been proposed to explain the potentially proarrhythmic 
effects of hyperglycemia in patients hospitalized with an AMI.41 Hyperglycemia can 
cause QT-interval prolongation and dispersion,95 which can trigger ventricular 
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arrhythmias in those with underlying coronary artery disease.96 Hyperglycemia has been 
associated with a larger infarct size, worse left ventricular function,94,97 and increases in 
serum markers of inflammation 41,97 which may promote the development of secondary 
cardiac arrhythmias. Hyperglycemia following an ischemic injury may also be a proxy of 
increased sympathetic activity, which could exert its proarrhythmic effects through 
elevated circulatory catecholamines and free fatty acids.98 Irrespective of the underlying 
mechanisms involved, the greater risk of developing VT among AMI patients with 
elevated glucose levels emphasizes the need for systematically assessing serum glucose 
levels at hospital admission and for more aggressive surveillance and treatment of 
patients with elevated glucose to reduce their risk of VT. 
Association of elevated serum glucose levels and timing of VT  
After adjusting for several potentially confounding variables, we found that 
patients with hyperglycemia were at increased risk for developing early VT. Early VT 
may be triggered by increased sympathetic activity or the inflammatory response to acute 
ischemic injury, each of which have been shown to be associated with elevated serum 
glucose levels in patients with AMI.16 Inflammatory responses to the acute ischemic 
insult predominately occur during the first few days after an AMI and are associated with 
increased resting membrane potential and prolonged action potential duration,41,97 which 
may contribute to the triggering of early VT.17  
While reperfusion therapy may induce reperfusion-associated cardiac 
arrhythmias, and may have contributed to some of the cases of early VT observed in the 
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present investigation, adjusting for reperfusion therapy did not materially change the 
estimated association of hyperglycemia with the development of VT. 
In addition, hyperglycemia was associated with a higher likelihood of developing 
late VT, a condition that usually occurs due to reentry pathways via isolated bundles of 
surviving myocytes at the border of the infarct.19 Late VT may also occur secondarily to 
developing heart failure or cardiogenic shock,94 which may be more prevalent in patients 
with a larger infarct, that is also associated with the hyperglycemic state.99  
In the present study, the elevated risk for developing late VT in patients with 
hyperglycemia was modestly attenuated after adjusting for heart failure and other 
potentially confounding factors of prognostic importance. This suggests that 
hyperglycemia may act by worsening left ventricular function to promote the onset of late 
VT. Inasmuch, efforts to reduce infarct size and improve left ventricular function may 
reduce the late proarrhythmic effects of hyperglycemia.  
Risk of VT in diabetic and nondiabetic patients with high serum glucose levels 
At hospital admission, patients with diabetes had higher serum glucose levels than 
patients without this metabolic disorder. However, these higher average glucose levels 
did not translate into a greater risk for VT. Several prior studies have also reported that, 
compared to patients without diabetes, patients with diabetes had a similar risk of 
developing new onset ventricular arrhythmias.48,100  
In separate analyses for patients with and without previously diagnosed diabetes, 
we found that glucose levels ≥140mg/dl at admission were associated with an increased 
risk of developing VT. In the aforementioned study in Spain, similar associations were 
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observed only among patients without, but not those with, a history of diabetes.48 
However, the authors of that study used a cutoff of 180mg/dl to define hyperglycemia 
and the risk of VT primarily increased when serum glucose levels were higher than 
120mg/dl in patients with diabetes. Inasmuch, high risk patients might have been 
included in the 2 comparison groups.48 In a sensitivity analysis using a ≥180mg/dl cutoff 
to define hyperglycemia, we similarly found an elevated risk of developing VT with 
hyperglycemia only in patients without previously diagnosed diabetes. 
Elevated sympathetic activity and acute inflammatory processes may play a larger 
role in inducing VT after AMI rather than the effect of chronic high concentrations of 
glucose itself. This hypothesis may also help to explain the significant association that we 
observed between hyperglycemia and the development of early, but not late VT, when 
sympathetic activation and the inflammatory response may subside. It is also possible 
that the antidiabetic therapies that patients with a history of diabetes might have received 
could have prevented or mitigated the onset of VT. However, these hypotheses remain 
speculative and warrant further investigation.  
Risk of VT in patients with STEMI and NSTEMI with high serum glucose levels   
Consistent with the results of prior studies,84 we found that VT occurred more 
frequently in patients with a STEMI than in those with an NSTEMI (22% vs. 13%). This 
may be due to the complete blockage of a coronary artery that occurs in patients with a 
STEMI and the subsequent development of hemodynamic disturbances and myocardial 
electrical instability. In the present study, when stratifying on the presence of the type of 
AMI, patients with hyperglycemia experienced a 30% elevated odds of developing VT 
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during their acute hospitalization. We are not aware of any previous study that has 
examined the relationship between elevated serum glucose levels and the risk of 
developing VT according to the 2 principal phenotypic expressions of AMI. The 
increased risk of VT associated with hyperglycemia suggests that close monitoring and 
treatment of hyperglycemia may reduce the risk of VT in patients with either a STEMI or 
an NSTEMI. 
Serum glucose levels and risk of developing VF   
Despite an initial higher risk of developing VF in patients with hyperglycemia at 
hospital admission, this risk was statistically insignificant after adjusting for important 
potential confounders. Other studies which used a composite outcome of VT and VF 
found an association between hyperglycemia and VAs.48,90 It was unclear if the 
association between hyperglycemia and VAs in prior studies was mainly driven by VT 
since VT is more common than VF and these studies did not examine VT and VF 
separately. The null association between hyperglycemia and VF in contrast with that of 
VT may suggest VF have different contributing factors, as a half of VF cases in the 
present study did not coexist with or develop from deteriorating VT. However, given less 
than 3% of patients developed VF in the present study, it is possible that we lack the 
statistical power to detect a meaningful association, and larger studies are warranted.  
Study strengths and limitations 
The present study has several strengths. We used data from a large, population-
based, investigation of patients hospitalized with AMI at all medical centers in central 
Massachusetts, all of whom were telemonitored for their entire hospital stay, thereby 
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minimizing the possibility of undiagnosed asymptomatic VT. However, some limitations 
of our observational study must also be noted. The in-hospital management of patients 
with hyperglycemia may affect the development of VAs, especially late VAs; however, 
we were unable to examine the impact of anti-hyperglycemic treatment since we did not 
collect data on the use of insulin or other antidiabetic medications. We also did not 
collect any information on changes in serum glucose levels during hospitalization for 
AMI, and, therefore, could not characterize the persistence of hyperglycemia throughout 
a patient’s acute hospitalization. 
Conclusions  
Hyperglycemia was associated with an increased risk for VT, especially within 
the first 48 hours after hospital admission, among patients hospitalized with validated 
AMI at all medical centers in central Massachusetts. Further studies are needed to more 
fully understand both the biologic mechanisms involved in the associations observed and 
the effects of hospital therapies that reduce serum glucose levels on the risk of developing 
VT following an AMI. 
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Table 0.1: Baseline characteristics of patients according to serum glucose levels at the time of 
hospital admission for an acute myocardial infarction 
Characteristics 
<140 mg/dl 
(n=1,949) 
≥140 mg/dl 
 (n= 2,191) 
p-value 
Age (median [IQR], years) 69 [57-81] 74 [63-82] <0.001 
Age (%)     <0.001 
<55 20.7 11.9  
55-64 20.4 16.3  
65-74 20.2 23.9  
≥75 38.8 48.0  
Men (%)   62.0 54.4 <0.001 
White (%)   93.0 92.5 0.58 
Medical History (%)        
Coronary artery disease 32.6 42.9 <0.001 
Heart failure 17.1 28.1 <0.001 
Chronic lung disease 15.6 19.2 0.002 
Chronic kidney disease 16.5 24.3 <0.001 
Diabetes  16.3 53.7 <0.001 
Hypertension  70.3 79.6 <0.001 
Hypercholesterolemia  61.8 62.6 0.59 
Stable angina 13.9 15.3 0.23 
Stroke/transient ischemic attack 12.2 16.0 <0.001 
Findings at admission    
Pulse (median [IQR], beat/min) 78 [67-92] 88 [74-104] <0.001 
SBP (median [IQR], mmHg)  141 [122-161] 140 [119-161] 0.18 
Troponin I (median [IQR], ng/mL) 0.51 [0.10-
3.50] 
0.50 [0.10-3.70] 0.72 
Potassium (median [IQR], mmol/L) 4.1 [3.8-4.5] 4.2 [3.9-4.7] <0.001 
Calcium (median [IQR], mg/dL) 9.1 [8.7-9.5] 9.0 [8.7-9.4] 0.002 
WBCC (median [IQR], 109cell/L) 8.9 [7.2-11.2] 10.4 [7.9-13.4] <0.001 
ST segment elevation  29.8 31.8 0.16 
In hospital complications (%)    
Acute kidney injury 10.4 19.3 <0.001 
Atrial fibrillation 16.7 22.1 <0.001 
Heart failure 25.9 45.5 <0.001 
Cardiogenic shock 2.4 6.5 <0.001 
Treatment during hospitalization (%)      
Aspirin  94.4 91.6 <0.001 
ACE-I/ARBs 67.7 73.3 <0.001 
Antiarrhythmic agents 14.6 18.9 <0.001 
Beta blockers 92.3 90.9 0.10 
Lipid lowering agents 77.2 74.1 0.018 
Thrombolytic therapy  2.3 2.4 0.74 
Percutaneous coronary intervention  51.6 42.0 <0.001 
CABG  7.1 6.9 0.80 
Length of stay (median [IQR], day) 4 [2-6] 4 [3-7] <0.001 
p-value from Chi-square test and Fisher’s exact test for categorical variables and Wilcoxon rank-sum test 
for continuous variables. 
IQR: interquartile range, WBCC: white blood cell count, ACE-I/ARBs: angiotensin converting enzyme 
inhibitor/angiotensin II receptor blockers, CABG: coronary artery bypass graft surgery. 
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Table 0.2: Association between serum glucose levels at the time of hospital admission and 
development of ventricular tachycardia (VT) in patients with acute myocardial infarction 
(n=4,140) 
  
Odd ratio (95% Confidence interval) 
Unadjusted  Adjusted  
Type of VT VT (IR) <140mg/dl ≥140mg/dl <140mg/dl ≥140mg/dl 
      
All VT  652 (15.7%) Reference  1.28 (1.08-1.51) Reference  1.48* (1.23-1.78) 
Early VT  434 (10.5%) Reference  1.21 (0.99-1.48) Reference  1.39† (1.11-1.73) 
Late VT  218 (5.32%) Reference  1.42 (1.07-1.87) Reference  1.19‡ (0.89-1.59) 
      
IR: incidence rate. 
Early VT was defined as VT occurred within 48 hours after hospital admission. 
*Adjusted for age, sex, race, and history of diabetes  
†Adjusted for age, sex, race, history of diabetes, and AMI subtype 
‡Adjusted for age, sex, race, and in-hospital heart failure complication 
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Table 0.3: Association between serum glucose levels at hospital admission and development of 
ventricular tachycardia (VT) in subgroups of patients with acute myocardial infarction  
Population VT/n 
Odd ratio (95% Confidence interval) 
Unadjusted Adjusted 
<140mg/dl ≥140mg/dl <140mg/dl ≥140mg/dl 
      
Diabetes status      
Diabetic  216/1,494 Reference  1.66 (1.11-2.47) Reference  1.72| (1.15-2.57) 
Nondiabetic  436/2,646 Reference  1.36 (1.10-1.67) Reference  1.41| (1.14-1.74) 
      
AMI subtype       
STEMI  281/1,277 Reference  1.17 (0.90-1.53) Reference  1.32| (1.00-1.73) 
NSTEMI  371/2,863 Reference  1.33 (1.07-1.66) Reference  1.30| (1.04-1.63) 
      
STEMI: ST segment-elevation myocardial infarction, NSTEMI: non-ST segment -elevation myocardial 
infarction, n: subsample 
|Adjusted for age, sex, and race 
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Table 0.4: Association between serum glucose levels at the time of hospital admission and 
development of ventricular fibrillation (VF) in patients with acute myocardial infarction 
(n=4,140) 
  
Odd ratio (95% Confidence interval) 
Unadjusted  Adjusted* 
 VF (IR) <140mg/dl ≥140mg/dl <140mg/dl ≥140mg/dl 
      
All VF  127 (3.07%) 
Reference  
1.73 (1.16-
2.59) 
Reference  
1.44 (0.92-
2.25) 
IR: incidence rate. 
*Adjusted for age, sex, race, history of diabetes, cardiogenic shock complication, and the presence of ST-
segment elevation 
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Figure 0.1: Distribution of serum glucose levels at hospital admission in patients who did and 
did not develop ventricular tachycardia after acute myocardial infarction 
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Figure 0.2: Incidence rates of ventricular tachycardia in decile groups of patients based on 
serum glucose levels (mg/dl) at hospital admission  
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Figure 0.3: Incidence rates of ventricular fibrillation in decile groups of patients based on 
serum glucose levels (mg/dl) at hospital admission 
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Figure 0.4: Distribution of serum glucose level at hospital admission in patients according to 
the presence of ventricular tachycardia (VT) or ventricular fibrillation (VF)  
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CHAPTER IV 
 
 
ASSOCIATION BETWEEN OCCURRENCE OF VENTRICULAR 
ARRHYTHMIAS AFTER AN ACUTE CORONARY SYNDROME AND 12-
MONTH PROGRESSION OF DEPRESSION AND ANXIETY 
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Abstract  
Background: Comorbid depression and anxiety are common and associated with worse clinical 
outcomes in patients hospitalized with an acute coronary syndrome (ACS). We investigated the 
association between serious ventricular arrhythmias (VAs) with progression of depression and 
anxiety among hospital survivors of an ACS. 
Methods: Patients were interviewed in hospital, and at 1, 3, 6, and 12 months after hospital 
discharge. The primary outcome was the presence of moderate/severe symptoms of depression 
and anxiety defined as a Patient Health Questionnaire (PHQ)-9 score ≥10 and a Generalized 
Anxiety Disorder (GAD)-7 score ≥10 at baseline and 1 month and PHQ-2≥3 and GAD-2≥3 at 3, 
6, and 12 months. We used marginal models to examine the association between VAs (ventricular 
tachycardia, ventricular fibrillation, cardiac arrest) and symptoms of depression or anxiety and 
PHQ-2 and GAD-2 scores over time.  
Results: Average age of the study population (n=2,074) was 61.1 years, 33.5% were women, and 
78.3% were white. VAs developed in 105 patients (5.1%). Symptoms of depression and anxiety 
were present in 22.2% and 23.5% of patients at baseline and declined to 14.1% and 12.6%, 
respectively, at 1 month post-discharge. Occurrence of VAs was not associated with progression 
of symptoms of depression (adjusted relative risk [aRR]=1.28, 95% Confidence interval 
[CI]=0.94-1.76) and anxiety (aRR=1.27, 95%CI=0.90-1.77), or with change in PHQ-2 and GAD-
2 scores over time, both before and after risk adjustment. 
Conclusion: The prevalence of symptoms of depression and anxiety were high after an ACS but 
quickly declined and were not associated with the occurrence of in-hospital VAs.  
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Introduction 
Among patients with an acute coronary syndrome (ACS), anxiety and depression 
is prevalent, with upwards of one quarter to one half of patients reporting symptoms of 
either condition.50,52,53 Moreover, these psychosocial disorders are highly interrelated, 
with coexistence in up to 80% of patients101,102, and are usually long-lasting following an 
ACS.54,103 Both depression and anxiety are associated with higher all-cause death rates, 
recurrent coronary events, and impaired quality of life.52,56-61 However, these conditions 
are often undiagnosed and/or under-treated in patients hospitalized for an ACS, and have 
been called for greater recognition and attention by the American Heart Association.62  
Serious ventricular arrhythmias following an ACS, including ventricular 
tachycardia (VT), ventricular fibrillation (VF), or cardiac arrest, may lead to additional 
stress and fear in patients, which could contribute to depression or anxiety. However, the 
impact of these life-threatening cardiac arrhythmias on the long-term progression of 
depression and anxiety among patients surviving an ACS has not been studied.  
Using data from a large and sociodemographically diverse population of patients 
discharged from the hospital after an ACS, we describe the 12-month progression of 
symptoms of depression and anxiety, and the impact of the in-hospital occurrence of life-
threatening ventricular arrhythmias, on the progression of symptoms of depression and 
anxiety during the subsequent year. 
Methods 
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Study design and population 
We used data from the Transitions, Risks, and Action in Coronary Events – 
Center for Outcomes Research and Education (TRACE-CORE) study for this 
investigation.104 In brief, TRACE-CORE is a multicenter prospective cohort study of adult 
men and women hospitalized with an ACS at three tertiary care and community medical 
centers in Worcester, MA, two hospitals in Atlanta, GA, and one hospital in Macon, GA, 
between April 2011 and May 2013. Each validated episode of an ACS was categorized as 
either an ST-segment elevation acute myocardial infarction (STEMI), a Non ST-segment 
elevation myocardial infarction (NSTEMI), or as unstable angina (UA).104 IRB approval 
was obtained from all participating sites and study subjects provided written informed 
consent. 
Trained study staff collected a wide range of patient sociodemographic, lifestyle, 
and psychosocial characteristics at baseline (in-person hospital interview) and at 1, 3, 6, 
and 12 months after discharge (via phone interview). We also collected information about 
patients’ clinical presentation, laboratory test results, and receipt of cardiac medications 
and coronary reperfusion therapy from hospital electronic medical records.104  
Measurement of symptoms of anxiety and depression  
Symptoms of anxiety and depression were assessed by the validated 7-item 
Generalized Anxiety Disorder (GAD)-7 questionnaire , range of scores from 0-21,105 and 
9-item Patient Health Questionnaire (PHQ)-9106, score range [0- 29], at baseline and first 
month post discharge, and by shorter versions, GAD-2 (score range [0-6])107 and PHQ-2 
(score range [0-6])108, at 3, 6, and 12 months post discharge to reduce participant burden. 
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Both the GAD and PHQ assess symptoms of anxiety and depression during the prior 2 
weeks. The questionnaires were conducted in person during the first 2-3 days of the 
patient’s index hospitalization (baseline interview) and by telephone interview at 1, 3, 6, 
and 12 months after hospital discharge. Due to its clinical significance, we chose the 
primary study outcome as the presence of moderate/severe symptoms of depression or 
anxiety, defined as scores of PHQ-9≥10 or PHQ-2≥3 for moderate/severe depression and 
GAD-7≥10 or GAD-2≥3 for moderate/severe anxiety. These cutoffs have been 
previously validated in general patient populations and in those with coronary heart 
disease. Each has sensitivity greater than 90% and specificity greater than 80%.107-110 We 
also generated the PHQ-2 and GAD-2 from the first two questions of the PHQ-9 and 
GAD-7, respectively, at baseline and 1 month and used scores of PHQ-2 and GAD-2 as 
our secondary study outcomes at all post hospital discharge time points. 
Life-threatening ventricular arrhythmias  
The occurrence of VT, VF, and cardiac arrest were based on physicians’ progress 
notes. To reduce misclassification of VT and VF due to underreporting of these 
arrhythmias in physicians’ notes, our research physicians also reviewed patients’ ECG 
strips in their hospital medical records. Ventricular tachycardia was defined as a cardiac 
arrhythmia of three or more consecutive complexes originating in the ventricles at a rate 
of greater than 100 beats per minute (cycle length less than 600 milliseconds).2 
Ventricular fibrillation was defined as a rapid, usually more than 300 beats per minute 
(cycle length 200 millisecond or less), grossly irregular,  ventricular rhythm with marked 
variability in QRS cycle length, morphology, and amplitude.2 Cardiac arrest was defined 
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as the sudden cessation of cardiac activity such that the victim became unresponsive 
without normal breathing or signs of circulation.63 Patients were considered as having a 
life-threatening ventricular arrhythmias (VAs) if they developed any of VT, VF, or 
cardiac arrest during their acute index hospital stay. 
Other covariates   
Comorbidity burden was assessed using the Charlson comorbidity index,111 and 
acute coronary event severity by the GRACE-risk score (based on age, heart rate, systolic 
blood pressure, Killip class, presence of renal failure, ST-segment deviation, cardiac 
arrest, and serum levels of creatinine and troponin.112 Additional important comorbidities 
that are not used in the Charlson index, such as hypertension, depression, and anxiety, 
were also noted. Cognitive function was measured using the Telephone Interview for 
Cognitive Status (TICS).113 Social support was measured by the 6-item Medical 
Outcomes Study Social Support Survey.114 Pharmacotherapy for depression or anxiety 
included receipt of serotonin reuptake inhibitors (SSRIs), serotonin–norepinephrine 
reuptake inhibitors (SNRIs) and oral benzodiazepines (lorazepam, diazepam, 
clonazepam, alprazolam, clorazepate, oxazepam, and chlordiazepoxide) as documented in 
medical records at hospital discharge. We also collected data on the hospital receipt of 
the following cardiac medications: aspirin, P2Y12 inhibitors (clopidogrel, prasugrel, 
ticagrelor, cangrelor), beta blockers, Angiotensin converting enzyme 
inhibitors/Angiotensin II receptor blockers (ACE-I/ARBs), and statins. 
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Missing data  
TRACE-CORE contains 2,222 participants with a verified acute coronary 
syndrome (ACS). After excluded 82 patients who died within 12 months of follow up, 
there were Among 1,836 patients who had complete data (medical record abstraction and 
in-person interview) at baseline (Appendix 5.12). Among them, 297 patients (16.2%) 
dropped out of the study after the baseline interview. Patients who dropped out after 
baseline were 3 years younger, less likely to be married/lived as married, less likely to 
have a college degree or higher education, more likely to be uninsured or under Medicaid 
coverage, had higher prevalence of history of selected diseases (chronic kidney disease, 
congestive heart failure, or depression), had longer hospital stay, and higher scores of 
depression or anxiety symptoms at baseline compared with patients who remained in the 
study (Appendix 5.13).  
Among 1,539 who remained in the study, 793 patients (51.5%) had complete data 
on symptoms of depression and anxiety at all time points while 746 patients had at least 
one missing variable of either symptoms of depression. The frequency of missing data for 
symptoms of depression and anxiety was lowest at first month (627 and 617, 
respectively) and highest at one year (742 and 741, respectively). The most common 
missing pattern is missing after the first month (8%) and missing at the first month (6%). 
Patients who had intermittent missing data were younger, more likely to being a non-
white race, less likely to be married/lived as married, had lower levels of education and 
health insurance compared with patients who had complete data at all time points. 
67 
 
67 
 
Patients who had intermittent data also had higher prevalence of depression and anxiety 
at baseline, as well as any time point during the follow-up (Appendix 5.14). 
Statistical analysis 
For this study, we excluded 82 patients who died within 1 year after hospital 
discharge and 55 patients with missing data on the symptoms of depression and anxiety at 
all time points. This left 2,074 patients with an independently confirmed ACS in this 
prospective study. Of these, 327 (15.8%) dropped out after the baseline hospital 
interview. Of the 1,747 patients who remained, 886 (50.7%) had missing data at one or 
more follow-up time points (1, 3, 6, and 12 months post discharge). We imputed 30 
datasets for each missing score of the PHQ-9, PHQ-2, GAD-7, and GAD-2 using 
multiple imputations by the chained equations method and predictive mean matching 
(PMM) models.115 The PMM took the observed score from a randomly chosen patient 
among 10 patients who had predictive scores that were most closely matched with the 
predictive score of a missing patient and then assigned that score to the missing 
patient.116 These models generate imputed scores that have a similar distribution to the 
observed scores, especially when the scores are discrete and bounded.116 All analyses 
were conducted in Stata 13.0. 
We compared the distributions of sociodemographic and clinical characteristics in 
patients who did and did not experience VAs at baseline, and described changes over the 
12-month follow up period in the prevalence of moderate/severe symptoms of depression 
and anxiety, as well as mean PHQ-2 and GAD-2 scores over time. We did this for all 
patients, and separately in patients with and without VAs, and in those without a history 
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of depression or anxiety. We used generalized estimating equations (GEE) with a Poisson 
distribution, a log link, robust variance estimation, and exchangeable correlation structure 
to estimate the relationship between VAs and progression of symptoms of depression and 
anxiety over following 12 months.117,118 The Charlson comorbidity index, GRACE-risk 
scores, and study sites were a priori included in all regression models. Other variables 
were tested iteratively, with those that changed estimates by more than 10% being 
retained in final models. We also re-analyzed the data after excluding patients with a 
history of depression or anxiety, since the impact of VAs on depression or anxiety 
progression could differ for these patients.  
Results 
Baseline characteristics 
The study population (n=2,074) was, on average, 61.1 years old, 33.5% were 
women, 78.3% were white and 15.5%, black. History of depression and anxiety was 
present in 255 (12.3%) and 177 (8.5%) patients, respectively, with 94 (4.5%) presented 
with a history of both condition. Among study patients, 105 patients (5.1%) developed at 
least one type of serious VAs, with 21 patients experiencing a cardiac arrest, 25 patients, 
VF, and 76, VT at some time during their acute hospitalization. 
Compared with patients who did not develop VAs, patients with VAs were, on 
average, about 2 years younger, had lower comorbidity burden as measured by the 
Charlson comorbidity index, were more likely to have developed heart failure, 
cardiogenic shock, or atrial fibrillation/flutter during hospitalization, were less likely to 
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have been hospitalized for unstable angina, and more likely to have undergone a PCI or 
coronary artery bypass graft surgery (CABG). They were also more likely to have been 
treated with beta-blockers or benzodiazepines during their acute hospitalization. (Table 
4.1).  
Progression of symptoms of depression and anxiety over time 
Depression and anxiety frequently coexisted, with 59.2% to 68.4% of patients 
who reported moderate/severe symptoms of depression also reporting moderate/severe 
symptoms of anxiety at the same time. At baseline, moderate/severe symptoms of 
depression were present in 22.2%, and anxiety in 23.5% of patients at baseline (Figure 
4.1, top panel). These prevalences rapidly declined to 14.1% and 12.6%, respectively, at 
1 month and remained relatively stable at the 12-month follow-up. Although the 
prevalence of moderate/severe symptoms of depression in patients with a history of 
depression (44.5%) and the prevalence of anxiety in patients with a history of anxiety 
(51.7%) were higher than among those without a history of depression (19.0%) or anxiety 
(20.9%), each of these patient groups experienced rapid decreases in their symptoms of 
these conditions during the first month post discharge, as did the overall patient 
population (Figure 1, middle and bottom panels).  
The prevalence of moderate/severe symptoms of depression and anxiety were 
slightly, but nonsignificantly, higher in patients with VAs compared with patients without 
VAs at baseline and during the first 3 months after hospital discharge; the frequencies of 
these conditions were similar at 6 and 12 months post discharge (Figure 4.2).  
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Association between VAs and progression of symptoms of depression and anxiety 
Since differences in the frequency of moderate/severe symptoms of depression 
and anxiety were most notable in the first 3 months after hospital discharge, we compared 
the risk of reporting symptoms of depression and anxiety during the first 3 months after 
hospital discharge between patients who did and did not develop VAs during their acute 
hospitalization. After adjusting for comorbidity burden, severity of the ACS episode, and 
study site, patients who developed in-hospital VAs at baseline had a insignificant 
elevated risk of developing symptoms of depression (adjusted Relative risk [aRR]= 1.28, 
95% Confidence interval [CI]=0.94-1.76) and anxiety (aRR=1.27, 95%CI=0.90-1.77) 
during the first 3 months post discharge compared with patients who did not developed 
VAs (Table 2). Similar findings were found for moderate/severe symptoms of depression 
(aRR=1.41 95%CI=0.99-2.02) and anxiety (aRR=1.22 95%CI=0.84-1.79) in our 
secondary sensitivity analysis when patients with a history of depression or anxiety were 
excluded.  
When we examined trends in symptoms of depression and anxiety, PHQ-2 and 
GAD-2 scores, depression and anxiety scores were similar for patients who did and did 
not develop VAs at all time points examined (Figure 4.3). In regression models, both 
before and after adjusting for several potentially confounding factors, VAs were not 
associated with higher scores of symptoms, depression or anxiety during the first 3 
months after hospital discharge (Table 4.4). 
Discussion  
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Comorbid depression and anxiety are common and have been shown to contribute 
to worse clinical outcomes in patients hospitalized for an ACS. In this study, the 
prevalence of moderate/severe symptoms of depression and anxiety quickly declined 
during the first month after hospital discharge and remained relatively stable thereafter. 
The occurrence of VAs had little effect on the symptoms of moderate/severe depression 
and anxiety in the short-term, and failed to show any significant association with the 
progression of symptoms of depression and anxiety over our 12-month follow-up period. 
Progression of symptoms of depression and anxiety 
We found that overall, the prevalence of moderate/severe symptoms of depression 
and anxiety rapidly declined by more than 50% in relative terms, from approximately 
25% to 12%, during the first month after hospital discharge for an ACS. Prior studies that 
have described the natural progression of symptoms of depression or anxiety in patients 
with coronary artery disease were based on very small patient samples,54,119 or were 
potentially biased due to complete-case analysis,119,120 including non-ACS patients,121 or 
having few reassessments of symptoms over a prolonged follow up period.119,120 For 
instance, one study of 226 women admitted to 4 hospitals for acute myocardial infarction 
(AMI) or CABG surgery in Melbourne, Australia found that more than 80% of patients 
experienced a decrease in their symptoms of depression and anxiety measured by the 
Hospital Anxiety and Depression Scale at 2 and 4 months post discharge, which remained 
at these levels throughout 12 months of follow up.121 On the other hand, a study of 287 
patients discharged after an AMI from 4 hospitals in the Netherlands between 2003 and 
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2005 found that symptoms of depression measured by the Beck Depression Inventory 
were similar across the baseline, 2, and 12 months post discharge assessments.54  
Stress and fear from an acute coronary event may contribute to the high 
“baseline” prevalence of moderate/severe symptoms of depression and anxiety that we 
observed. We found such feelings to be less common thereafter, starting at the first month 
post discharge. Other factors, including the in-hospital setting of the baseline interview 
during the patient’s acute hospitalization, might have also triggered worse self-reported 
symptoms compared with the later time points, when patients were interviewed via 
telephone at home. Regardless of the underlying reasons or contributory causes, our 
findings suggest that a single screening for symptoms of depression and anxiety during 
the acute hospital stay may overestimate the continuing burden of these comorbidities in 
patients who have experienced an ACS. Since the prevalence of moderate/severe 
symptoms of depression and anxiety were stable after 1 month, screening for the 
symptoms of depression or anxiety in the outpatient setting may be more useful than an 
in-hospital assessment after an acute coronary event.  
On the other hand, several studies using latent group analysis have suggested that 
patients with coronary artery disease may be usefully classified into several groups with 
distinct trajectories of depression and/or anxiety over time.103,121-123 These studies, despite 
being based on relatively few patients, suggest that serial measurement of symptoms of 
depression and anxiety may be needed to identify high-risk patients with worsening 
psychosocial trajectories who are most likely to benefit from post-discharge 
interventions. However, when, where, and how to screen for a level of sustained 
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depression and anxiety following an acute coronary event that may warrant further 
intervention deserves further study.  
As expected, patients with a history of depression or anxiety were more likely to 
report these problems that patients without these pre-existing conditions. However, 
despite baseline differences, the progression of symptoms of depression and anxiety over 
the subsequent several months was similar for the two groups. This suggests that acute 
stress or fear that patients have after the ACS may only exert an acute impact on the 
symptoms of depression and anxiety, but are not likely to change the chronic course of 
these symptoms in patients with a history of depression or anxiety. We also note that the 
progression of depression was similar to that of anxiety during one year of follow up. 
This was perhaps due to the fact that close to two-thirds of patients with moderate/severe 
symptoms of either depression or anxiety reported symptoms of both conditions. These 
findings appear to reflect the close clinical association between these two conditions, 
which may share long-term trajectories of progression, and suggests the value of 
screening for both conditions simultaneously.  
Association between VAs and progression of symptoms of depression and anxiety 
To our knowledge, the present study is first to examine the association between 
occurrence of a serious VA in the hospital and progression of symptoms of depression 
and anxiety among patients discharged following an ACS. Although patients with VAs 
were somewhat more likely to report moderate/severe symptoms of depression or anxiety 
during the first 3 months after hospital discharge than other patients, these differences 
were not statistically significant. In both unadjusted and adjusted analyses, the 
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development of VAs was not associated with a greater risk of having symptoms of 
depression or anxiety at 3 months after hospital discharge. These results were confirmed 
in a secondary analysis, in which we measured depression and anxiety as numerical 
scores. In contrast to our initial expectation, experiencing a serious VA after an ACS does 
not appear to increase the risk of developing moderate/severe symptoms of depression or 
anxiety in the first year following hospital discharge. Note that only 105 (5.1%) of our 
study population developed these clinically significant cardiac arrhythmias: a larger study 
might be able to detect differences in the symptoms of depression and anxiety associated 
with VAs. However, our study suggests that such differences are unlikely to be 
particularly large.  
Study strengths and limitations  
This study is first to examine the psychological impact of VAs in patients 
hospitalized with ACS and post-discharge trends in symptoms of depression and anxiety 
over time. It used a large, geographically and sociodemographically diverse patient 
population. Rich socioeconomic and clinical data were available, allowing us to adjust for 
many potentially important confounders. The study also has important limitations. While 
patients’ perceived susceptibility might be different for sustained VT (more dangerous) 
than nonsustained VT (usually self-limited), we did not collect information on the type of 
VT that occurred during the patients’ acute hospital stay. In addition, although we have 
addressed missing data using statistically sound methods, there were substantial amounts 
of missing follow-up data. 
Conclusions 
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In this study of a large and diverse population discharged from the hospital after 
an ACS, prevalence of self-reported moderate/severe symptoms of depression and of 
anxiety were both high at the time of an in-hospital index interview, but substantially 
declined during the month post hospital discharge and remained stable thereafter. The 
occurrence of VAs was not associated with an elevated risk of moderate/severe 
symptoms of depression or anxiety after hospital discharge. Future studies should seek to 
identify an appropriate post-hospital time to screen for depression and anxiety in the 
setting of an ACS, and find an efficient way to identify patients at high risk, where 
intervention efforts might do the most good.  
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Table 0.1: Baseline characteristics of patients discharged from the hospital after an acute 
coronary syndrome according to the presence of serious ventricular arrhythmia (VAs) 
 With VAs (n=105) 
Without VAs (n= 
1,969) 
p-value  
Age (mean, years) 58.8 61.2 <0.001 
Women (%) 23.8 34.0 0.031 
Race/ethnicity (%)    
White 81.8 78.1 0.64  
Black 15.7 15.7   
Other 5.8 6.3   
Marital status (%)    
Married/lived as married 60.0 58.8 0.29  
Separate/divorced/widowed 24.8 30.2   
Single/never married 15.2 11.1   
Educational attainment (%)    
College graduate or higher  26.7 25.2 0.68  
Some technical school or college  26.7 29.0   
High school graduate 33.3 29.2   
Less than high school 13.3 16.6   
Insurance coverage (%)    
Medicare plus private insurance 15.2 18.7 0.54  
Private insurance only 50.5 49.6   
Medicare only 13.3 13.2   
Medicaid  8.6 10.4   
Uninsured  12.4 8.1   
Unemployed/retired (%) 54.3 58.1 0.44 
Social support (mean) 20.6 20.1 0.29 
Disease impact scale (mean) 34.6 32.6 0.50 
Cognitive function (mean) 32.2 31.7 0.21 
Previously diagnosed (%)     
Anxiety  4.8 8.7 0.16 
Depression  7.6 12.5 0.14 
Hypertension  68.6 75.4 0.12 
Charlson Comorbidity Index (mean) 2.7 3.3 0.013 
Physiologic findings at admission (mean)    
Systolic blood pressure (mmHg) 135.5 142.4 0.008 
Diastolic blood pressure (mmHg) 80.0 80.6 0.75 
Heart rate (beat/min) 83.0 77.3 0.002 
GRACE risk score  94.4 94.3 0.98 
In hospital complications (%)    
Acute kidney injury 8.6 4.9 0.10 
Heart failure/cardiogenic shock 8.6 2.1 <0.001 
Atrial fibrillation/flutter  18.1 6.4 <0.001 
ACS Type (%)    
Unstable angina 18.1 32.1 0.003 
STEMI  27.6 17.5  
NSTEMI 54.3 50.4  
Reperfusion treatment received (%)    
Medical treatment 8.6 20.6 0.004 
PCI 72.4 67.5  
CABG 19.0 11.8  
Medications at hospital discharge (%)    
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Aspirin 97.1 96.5 0.74 
P2Y12 inhibitors  89.5 84.9 0.20 
ACE-I/ARBs  64.8 61.8 0.54 
Beta-blockers 97.1 89.3 0.017 
Statins  88.6 86.8 0.61 
SSRI/SNRIs 15.2 16.2 0.79 
Benzodiazepines 41.0 29.1 0.010 
Length of hospital stay (days) 6.0 4.9 0.70 
30-day hospital readmission (%) 12.4 11.8 0.85 
NSTEMI: non-ST-segment elevation myocardial infarction, STEMI: ST-segment elevation myocardial 
infarction, PCI: percutaneous coronary intervention, CABG: coronary artery bypass graft surgery, ACE-
I/ARBs: Angiotensin converting enzyme inhibitor/Angiotensin receptor blockers, SSRI: selective 
serotonin reuptake inhibitors, SNRI: serotonin and norepinephrine reuptake inhibitors. 
Benzodiazepines: lorazepam, diazepam, clonazepam, alprazolam, clorazepate, oxazepam, 
chlordiazepoxide. 
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Figure 0.1: Prevalence of moderate/severe symptoms of depression and anxiety overall and by 
the presence of a history of these conditions among patients discharged from the  hospital after 
an acute coronary syndrome. 
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Figure 0.2: Prevalence of moderate/severe symptoms of depression and anxiety among 
patients discharged from the hospital after an acute coronary syndrome, with and without in-
hospital serious ventricular arrhythmias at baseline. Higher scores mean worse symptoms 
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Table 0.2: Association (Relative risk, 95%Confidence interval) between occurrence of in-
hospital serious ventricular arrhythmia and progression of moderate/severe symptoms of 
depression and anxiety in the first 3 months following hospital discharge in patients with an 
acute coronary syndrome.  
 Depression  Anxiety 
 Unadjusted Adjusted† Unadjusted Adjusted† 
     
All patients      
Arrhythmia  1.18 (0.86-1.63) 1.28 (0.94-1.76)  1.17 (0.84-1.64) 1.27 (0.90-1.77)  
Time (month) 0.83 (0.79-0.87) 0.83 (0.79-0.87)  0.82 (0.78-0.86) 0.82 (0.78-0.86)  
     
Patients without a history of depression or anxiety    
Arrhythmia  1.30 (0.90-1.88) 1.41 (0.99-2.02) 1.22 (0.84-1.79) 1.22 (0.84-1.79) 
Time (month) 0.82 (0.77-0.87) 0.82 (0.77-0.87) 0.81 (0.76-0.86) 0.81 (0.76-0.86) 
Estimates are from generalized estimating equation marginal models with exchangeable correlation 
matrix.  
†Additionally adjusted for the Charlson comorbidity index, GRACE risk score, and study site 
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Figure 0.3: Mean scores of symptoms of depression (PHQ 2) and anxiety (GAD 2) over time, 
separately for those with and without serious ventricular arrhythmias in patients discharged 
from the hospital following an acute coronary syndrome. Higher scores mean worse symptoms 
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Table 0.3: Differences in mean score (95% Confidence Interval) of depression (PHQ-2) and 
anxiety (GAD-7) symptoms during the first 3 months following hospital discharge between 
patients with and without in-hospital serious ventricular arrhythmias after an acute coronary 
syndrome  
 Depression  Anxiety 
 Unadjusted Adjusted Unadjusted Adjusted 
     
Arrhythmia  0.04 (-0.23; 0.30) 0.14 (-0.11; 0.39)† 0.02 (-0.30; 0.34) 0.04 (-0.26; 0.34)‡ 
Time (month) -0.10 (-0.13; -0.08) -0.10 (-0.13; -0.08)† -0.25 (-0.28; -0.23) -0.25 (-0.28; -0.23)‡ 
Estimates are from generalized estimating equation marginal models with exchangeable correlation 
matrix. Positive or negative scores mean higher or lower symptoms, respectively. 
†Additionally adjusted for the Charlson comorbidity index, GRACE risk score, study sites, and history of 
depression. 
‡Additionally adjusted for Charlson comorbidity index, GRACE risk score, study sites, age, sex, history of 
depression, and the use of benzodiazepines  
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APPENDICES 
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Chapter 2 
Appendix 0-1: Raw data for Figure 1, top and middle panels: actual counts of VF and VF episodes in patients with acute 
myocardial infarction in each study year 
 All VT VF Primary VT/VF Secondary VT/VF 
Year Number of patients None VT only   VF  None VT only   VF  None VT only VF  
1986 685 525 101 59 290 49 25 235 52 34 
1988 603 474 83 46 289 31 17 185 52 29 
1990 724 566 117 41 328 51 13 238 66 28 
1991 824 621 152 51 366 75 21 255 77 30 
1993 918 674 185 59 416 97 28 258 88 31 
1995 930 734 137 59 444 77 25 290 60 34 
1997 946 798 94 54 526 57 20 272 37 34 
1999 935 755 133 47 461 65 11 294 68 36 
2001 1,193 957 185 51 580 100 20 377 85 31 
2003 1,020 810 179 31 465 99 11 345 80 20 
2005 890 751 110 29 463 61 8 288 49 21 
2007 780 647 110 23 402 55 11 245 55 12 
2009 702 608 85 9 433 51 4 175 34 5 
2011 675 600 60 15 416 36 11 184 24 4 
Total 11,825 9,520 1,731 574 5,879 904 225 3,641 827 349 
Note: VF is with or without VT. 
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Appendix 0-2: Raw data for Figure 1, bottom panel: In-hospital death for patients with acute myocardial infarction complicating by 
ventricular tachycardia or ventricular fibrillation  
 
Study year  
Status 1986 1988 1990 1991 1993 1995 1997 1999 2001 2003 2005 2007 2009 
201
1 
VF 
Alive  28 25 14 27 25 33 33 23 25 17 15 17 4 11 
Dead  31 21 27 24 34 26 21 24 26 14 14 6 5 4 
Total 59 46 41 51 59 59 54 47 51 31 29 23 9 15 
VT 
Alive  75 58 97 128 161 124 82 113 164 159 97 98 77 58 
Dead  26 25 20 24 24 13 12 20 21 20 13 12 8 2 
Total 101 83 117 152 185 137 94 133 185 179 110 110 85 60 
No 
VT/VF 
Alive  470 414 504 556 611 658 720 694 863 753 693 588 583 570 
Dead  55 60 62 65 63 76 78 61 94 57 58 59 25 30 
Total 525 474 566 621 674 734 798 755 957 810 751 647 608 600 
VT: ventricular tachycardia, VF: ventricular fibrillation, with/without VT.  
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Appendix 0-3: Raw data for figure 2, top panel: frequency of early and late ventricular 
tachycardia and ventricular fibrillation in patients with acute myocardial infarction  
Arrhythmia Timing 
Year  
2001 2003 2005 2007 2009 2011 Total 
VT 
Early  67 94 58 80 45 33 377 
Late  62 48 25 22 22 7 186 
All  129 142 83 102 67 40 563 
VF 
Early  11 11 12 15 2 8 59  
Late  12 11 7 2 5 3 40  
All  23 22 19 17 7 11 99  
Total patients   762 729 695 703 532 448 3,869  
VT: ventricular tachycardia, VF: ventricular fibrillation, with/without ventricular tachycardia  
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Appendix 0-4: Raw data for figure 2, bottom panel: Frequency of ventricular 
tachycardia and ventricular fibrillation in patients with ST-segment elevation and non-
ST-segment elevation myocardial infarction 
  Year  
 
Arrhythmi
a  2001 2003 2005 2007 2009 2011 Total 
STEMI 
None 198 164 151 167 98 95 873 
VT  46 72 32 36 20 22 228 
VF  13 16 12 12 0 7 60 
Total 257 252 195 215 118 124 1,161 
NSTEMI 
None 412 401 442 417 360 302 2,334  
VT  83 70 51 66 47 18 335  
VF  10 6 7 5 7 4 39  
Total 505 477 500 488 414 324 2,708  
VT: ventricular tachycardia, VF: ventricular fibrillation, with/without VT  
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Appendix 0-5: Regression coefficients for trends in the incidence rates of ventricular 
tachycardia among patients hospitalized for an acute myocardial infarction between 
1986 and 2011 
 RR Robust SE z P>z 95% CI 
       
Trends (in 10 years) 0.885 0.041 -2.620 0.009 0.808 0.970 
       
Age (in years)       
55-64 0.846 0.059 -2.410 0.016 0.739 0.969 
65-74 0.829 0.056 -2.760 0.006 0.726 0.947 
>=75 0.767 0.054 -3.740 0.000 0.667 0.881 
       
Sex  1.431 0.070 7.330 0.000 1.300 1.575 
Non-white  0.780 0.087 -2.220 0.026 0.627 0.971 
History of heart failure  1.153 0.068 2.410 0.016 1.027 1.295 
History of diabetes 0.861 0.044 -2.910 0.004 0.779 0.953 
History of hypertension 0.921 0.043 -1.780 0.075 0.841 1.008 
History of stroke 0.909 0.067 -1.290 0.197 0.787 1.051 
Serum potassium (in mg/dl) 0.957 0.032 -1.340 0.181 0.897 1.021 
Atrial fibrillation complication 1.301 0.074 4.660 0.000 1.165 1.454 
Heart failure complication 1.277 0.064 4.920 0.000 1.159 1.408 
Cardiogenic shock complication  1.462 0.109 5.090 0.000 1.263 1.692 
Aspirin  0.908 0.058 -1.520 0.129 0.801 1.029 
ACE-I/ARBs 1.122 0.058 2.250 0.025 1.015 1.241 
Antiarrhythmic agents 1.788 0.090 11.490 0.000 1.619 1.974 
Beta blockers 1.079 0.064 1.290 0.198 0.961 1.211 
Lipid lowering agents 1.127 0.067 2.000 0.046 1.002 1.267 
Thrombolysis therapy 1.751 0.098 10.010 0.000 1.569 1.954 
PCI  1.127 0.065 2.080 0.038 1.007 1.261 
CABG  0.959 0.087 -0.460 0.644 0.803 1.146 
Length of stay (in day) 1.013 0.002 7.090 0.000 1.010 1.017 
_constant  0.122 0.020 -13.040 0.000 0.089 0.167 
RR: relative risk, SE: standard error, CI: confidence interval, ACE-I/ARBs: Angiotensin converting 
enzyme inhibitors/Angiotensin receptor blockers, PCI: percutaneous coronary intervention, CABG: 
coronary artery bypass graft surgery  
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Appendix 0-6: Regression coefficients for trends in the incidence rates of ventricular 
fibrillation among patients hospitalized for an acute myocardial infarction between 
1986 and 2011 
 RR Robust SE z P>z 95% CI 
       
Trends (in 10 years) 0.796 0.065 -2.800 0.005 0.678 0.934 
       
Age (in years)       
55-64 0.837 0.101 -1.470 0.140 0.661 1.060 
65-74 0.872 0.106 -1.120 0.261 0.686 1.107 
>=75 0.637 0.085 -3.380 0.001 0.490 0.827 
       
Sex  1.599 0.140 5.350 0.000 1.347 1.899 
Non-white  1.021 0.180 0.120 0.906 0.722 1.443 
History of heart failure  0.818 0.096 -1.710 0.088 0.650 1.030 
History of diabetes 0.822 0.079 -2.030 0.042 0.681 0.993 
History of hypertension 1.030 0.086 0.360 0.721 0.875 1.213 
History of stroke 0.869 0.124 -0.990 0.322 0.657 1.148 
Serum potassium (in mg/dl) 0.646 0.049 -5.770 0.000 0.557 0.749 
Atrial fibrillation complication 1.259 0.123 2.350 0.019 1.039 1.525 
Heart failure complication 1.355 0.124 3.310 0.001 1.132 1.621 
Cardiogenic shock complication  3.661 0.352 13.480 0.000 3.031 4.421 
Aspirin  0.712 0.072 -3.340 0.001 0.583 0.869 
ACE-I/ARBs 1.053 0.099 0.550 0.583 0.876 1.266 
Antiarrhythmic agents 2.955 0.258 12.410 0.000 2.490 3.506 
Beta blockers 0.707 0.063 -3.910 0.000 0.594 0.841 
Lipid lowering agents 0.753 0.088 -2.420 0.015 0.599 0.947 
Thrombolysis therapy 1.529 0.152 4.280 0.000 1.259 1.857 
PCI  1.365 0.144 2.960 0.003 1.111 1.678 
CABG  0.860 0.151 -0.860 0.389 0.610 1.212 
Length of stay (in day) 1.007 0.002 3.280 0.001 1.003 1.011 
_constant  0.706 0.225 -1.100 0.274 0.378 1.317 
RR: relative risk, SE: standard error, CI: confidence interval, ACE-I/ARBs: Angiotensin converting 
enzyme inhibitors/Angiotensin receptor blockers, PCI: percutaneous coronary intervention, CABG: 
coronary artery bypass graft surgery 
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Appendix 0-7: Regression coefficients for trends in the mortality rates of patients who 
had ventricular tachycardia complicating acute myocardial infarction  
 RR Robust SE z P>z 95% CI 
       
Trends (in 10 years) 1.093 0.133 0.730 0.463 0.862 1.387 
       
Age (in years)       
55-64 1.701 0.594 1.520 0.128 0.859 3.372 
65-74 2.335 0.774 2.560 0.010 1.220 4.470 
>=75 3.420 1.126 3.730 0.000 1.794 6.521 
       
Sex  0.830 0.094 -1.660 0.098 0.665 1.035 
Non-white  1.848 0.456 2.490 0.013 1.139 2.998 
History of heart failure  1.333 0.166 2.310 0.021 1.044 1.702 
History of diabetes 0.975 0.119 -0.210 0.837 0.767 1.239 
History of hypertension 1.017 0.126 0.140 0.889 0.798 1.297 
History of stroke 1.107 0.180 0.620 0.533 0.805 1.523 
Serum potassium (in mg/dl) 1.383 0.095 4.730 0.000 1.209 1.582 
Atrial fibrillation complication 1.169 0.137 1.330 0.183 0.929 1.472 
Heart failure complication 1.475 0.191 3.000 0.003 1.144 1.902 
Cardiogenic shock complication  3.105 0.350 10.060 0.000 2.490 3.872 
Aspirin  0.659 0.086 -3.200 0.001 0.510 0.851 
ACE-I/ARBs 0.544 0.072 -4.570 0.000 0.419 0.706 
Antiarrhythmic agents 1.549 0.181 3.750 0.000 1.232 1.947 
Beta blockers 0.684 0.085 -3.050 0.002 0.537 0.873 
Lipid lowering agents 0.612 0.119 -2.520 0.012 0.418 0.897 
Thrombolysis therapy 0.970 0.178 -0.170 0.868 0.677 1.389 
PCI  0.749 0.142 -1.530 0.127 0.516 1.086 
CABG  0.612 0.197 -1.520 0.128 0.326 1.151 
Length of stay (in day) 0.974 0.008 -3.120 0.002 0.959 0.990 
_constant  0.022 0.010 -8.830 0.000 0.010 0.052 
RR: relative risk, SE: standard error, CI: confidence interval, ACE-I/ARBs: Angiotensin converting 
enzyme inhibitors/Angiotensin receptor blockers, PCI: percutaneous coronary intervention, CABG: 
coronary artery bypass graft surgery  
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Appendix 0-8: Regression coefficients for trends in the mortality rates of patients who 
had ventricular fibrillation complicating acute myocardial infarction 
 RR Robust SE z P>z 95% CI 
       
Trends (in 10 years) 1.075 0.090 0.870 0.386 0.913 1.266 
       
Age (in years)       
55-64 1.418 0.268 1.850 0.064 0.979 2.054 
65-74 1.567 0.288 2.450 0.014 1.094 2.245 
>=75 1.970 0.349 3.820 0.000 1.392 2.789 
       
Sex  0.839 0.059 -2.490 0.013 0.731 0.963 
Non-white  1.077 0.187 0.430 0.669 0.766 1.515 
History of heart failure  1.042 0.093 0.460 0.648 0.874 1.241 
History of diabetes 1.257 0.091 3.150 0.002 1.090 1.449 
History of hypertension 1.112 0.084 1.400 0.162 0.958 1.290 
History of stroke 1.439 0.136 3.860 0.000 1.196 1.732 
Serum potassium (in mg/dl) 1.080 0.047 1.740 0.081 0.990 1.177 
Atrial fibrillation complication 0.994 0.084 -0.070 0.941 0.843 1.172 
Heart failure complication 1.153 0.090 1.820 0.068 0.989 1.345 
Cardiogenic shock complication  1.601 0.113 6.690 0.000 1.395 1.838 
Aspirin  0.871 0.074 -1.630 0.103 0.738 1.028 
ACE-I/ARBs 0.759 0.086 -2.440 0.015 0.608 0.947 
Antiarrhythmic agents 1.256 0.097 2.950 0.003 1.079 1.461 
Beta blockers 0.788 0.069 -2.740 0.006 0.664 0.935 
Lipid lowering agents 0.758 0.105 -2.000 0.045 0.579 0.994 
Thrombolysis therapy 0.736 0.084 -2.680 0.007 0.587 0.921 
PCI  0.536 0.067 -4.960 0.000 0.418 0.686 
CABG  0.728 0.227 -1.020 0.309 0.395 1.342 
Length of stay (in day) 0.983 0.009 -1.920 0.054 0.966 1.000 
_constant  0.281 0.074 -4.810 0.000 0.167 0.471 
RR: relative risk, SE: standard error, CI: confidence interval, ACE-I/ARBs: Angiotensin converting 
enzyme inhibitors/Angiotensin receptor blockers, PCI: percutaneous coronary intervention, CABG: 
coronary artery bypass graft surgery  
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Chapter 4 
Appendix 0-9: Patterns of progression of symptoms of depression 12-month post discharge in 
patients with non-missing data (TRACE-CORE) 
Depression 0 Depression 1 Depression 3 Depression 6 Depression 12 Frequency Percent 
0 0 0 0 0 603 73.36 
0 0 0 0 1 9 1.09 
0 0 0 1 0 11 1.34 
0 0 0 1 1 2 0.24 
0 0 1 0 0 22 2.68 
0 0 1 0 1 2 0.24 
0 0 1 1 0 1 0.12 
0 0 1 1 1 5 0.61 
0 1 0 0 0 17 2.07 
0 1 0 0 1 1 0.12 
0 1 0 1 1 1 0.12 
0 1 1 0 0 1 0.12 
0 1 1 0 1 2 0.24 
0 1 1 1 0 1 0.12 
0 1 1 1 1 3 0.36 
1 0 0 0 0 58 7.06 
1 0 0 0 1 6 0.73 
1 0 0 1 0 9 1.09 
1 0 0 1 1 1 0.12 
1 0 1 0 0 6 0.73 
1 0 1 0 1 2 0.24 
1 0 1 1 0 2 0.24 
1 1 0 0 0 12 1.46 
1 1 0 0 1 5 0.61 
1 1 0 1 0 2 0.24 
1 1 0 1 1 4 0.49 
1 1 1 0 0 9 1.09 
1 1 1 0 1 2 0.24 
1 1 1 1 0 10 1.22 
1 1 1 1 1 13 1.58 
Frequency Missing = 1086 
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Appendix 0-10: Patterns of progression of symptoms of anxiety 12-month post discharge in 
patients with non-missing data (TRACE-CORE) 
Anxiety 0 Anxiety 1 Anxiety 3 Anxiety 6 Anxiety 12 Frequency Percent 
0 0 0 0 0 598 72.14 
0 0 0 0 1 14 1.69 
0 0 0 1 0 9 1.09 
0 0 0 1 1 6 0.72 
0 0 1 0 0 17 2.05 
0 0 1 0 1 3 0.36 
0 0 1 1 0 5 0.60 
0 0 1 1 1 2 0.24 
0 1 0 0 0 8 0.97 
0 1 0 0 1 3 0.36 
0 1 0 1 0 2 0.24 
0 1 0 1 1 1 0.12 
0 1 1 0 0 1 0.12 
0 1 1 0 1 5 0.60 
0 1 1 1 0 3 0.36 
0 1 1 1 1 1 0.12 
1 0 0 0 0 67 8.08 
1 0 0 0 1 6 0.72 
1 0 0 1 0 8 0.97 
1 0 0 1 1 5 0.60 
1 0 1 0 0 6 0.72 
1 0 1 0 1 2 0.24 
1 0 1 1 0 1 0.12 
1 0 1 1 1 3 0.36 
1 1 0 0 0 10 1.21 
1 1 0 0 1 5 0.60 
1 1 0 1 0 4 0.48 
1 1 0 1 1 2 0.24 
1 1 1 0 0 7 0.84 
1 1 1 0 1 1 0.12 
1 1 1 1 0 6 0.72 
1 1 1 1 1 18 2.17 
Frequency Missing = 1079 
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Appendix 0-11: Characteristics of patients discharged from the hospital after an acute coronary 
syndrome according to missing baseline data (TRACE-CORE) 
 
Missing data Complete data 
p-value  
n=304 n=1,836 
Age (years)         64 [56-72]         61 [53-69] <0.001 
Age group (%)   <0.001 
<55 22.2 30.7  
55-64 29.1 32.0  
65-75 30.8 25.0  
≥75 18.0 12.4  
Women (%) 35.9 32.9 0.28 
Race/ethnicity (%)     0.41 
White 75.2 78.3  
Black 17.2 15.8  
Other 7.5 5.9  
Marital status (%)     0.28 
Married/lived as married 56.7 58.7  
Separate/divorced/widowed 33.5 29.7  
Single/never married 9.7 11.7  
Educational attainment (%)     0.001 
College graduate or higher  21.7 25.3  
Some technical school or college  28.6 28.9  
High school graduates 25.4 30.3  
Less than high school 24.3 15.5  
Insurance coverage (%)     0.011 
Medicare plus private insurance 19.8 18.6  
Private insurance only 42.0 50.2  
Medicare only 18.9 12.6  
Medicaid  11.5 10.2  
Uninsured  7.7 8.4  
Unemployed/retired (%) 67.8 57.3 <0.001 
Previously diagnosed (%)      
Anxiety  10.1 8.4 0.28 
Chronic kidney disease 14.3 9.9 0.011 
Congestive heart failure  18.1 12.8 0.006 
Coronary artery disease 28.8 25.9 0.25 
Depression  10.9 12.7 0.33 
Diabetes  31.6 37.8 0.022 
Hypertension 70.5 75.2 0.06 
Physiologic findings at admission     
Systolic blood pressure (mmHg)      137 [119-155]        141 [125-157] 0.007 
Diastolic blood pressure (mmHg)         74 [65-84]         80 [70-91] <0.001 
Heart rate (beat/min)         74 [63-85]         75 [65-88] 0.028 
Laboratory findings at admission     
Creatinine (mg/dl) 1 [.84-1.25] 0.97 [.81-1.17] 0.010 
Glucose (mg/dl)        132 [106-183]        126 [105-168] 0.20 
GRACE risk score  102.5 [78.2-122.1] 92.2 [74.1-111.7] <0.001 
Potassium (mmol/l) 4.4 [4.1-6.4]        4.3 [4-7.1] 0.034 
White blood cell count (109 cell/L) 10.8 [8.2-35.7] 10.9 [8.5-43.3] 0.17 
In hospital complications (%)     
Acute kidney injury 5.7 5.4 0.81 
Heart failure/cardiogenic shock 1.6 1.9 0.64 
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Atrial fibrillation/flutter  5.7 7.4 0.24 
ACS Type (%)     <0.001 
Unstable angina 39.8 29.6  
STEMI  12.8 18.7  
NSTEMI 47.4 51.7  
Reperfusion treatment received (%)     <0.001 
Medical treatment 38.3 19.4  
PCI 53.1 68.1  
CABG 8.6 12.5  
Medications at hospital discharge (%)      
Aspirin 92.0 97.1 <0.001 
P2Y12 inhibitors  79.5 85.3 0.005 
ACE-I/ARBs  57.5 62.4 0.08 
Beta-blockers 86.8 90.1 0.05 
Statins  79.8 87.9 <0.001 
SSRI/SNRI/atypical antidepressants 14.5 16.5 0.33 
Benzodiazepines 32.6 29.3 0.19 
Length of hospital stay (days)         2 [1-5] 3 [2-5] <0.001 
Depression symptoms score    
Baseline [0-27]          4 [2-8]          4 [2-9] 0.67 
1 month [0-27]          3 [1-7]    2 [1-6] 0.32 
3 months [0-6]          1 [0-6]          1 [0-6] 0.57 
6 months [0-6]          0 [0-1] 0 [0-1] 0.63 
12 months [0-6]          0 [0-1] 0 [0-1] 0.96 
Anxiety symptoms     
Baseline [0-21]          5 [1-10]   4 [1-9] 0.28 
1 month [0-21]          2 [0-6] 2 [1-5] 0.45 
3 months [0-6]          0 [0-2] 0 [0-1] 0.27 
6 months [0-6]          0 [0-1] 0 [0-1] 0.63 
12 months [0-6]          0 [0-2] 0 [0-1] 0.33 
Note: continuous variables were reported in median [interquartile range] 
NSTEMI: non-ST-segment elevation myocardial infarction, STEMI: ST-segment elevation myocardial 
infarction, PCI: percutaneous coronary intervention, CABG: coronary artery bypass graft surgery, ACE-
I/ARBs: Angiotensin converting enzyme inhibitor/Angiotensin receptor blockers, SSRI: selective serotonin 
reuptake inhibitors, SNRI: serotonin and norepinephrine reuptake inhibitors. 
Atypical antidepressants included bupropion, mirtazapine, nefazodone. Benzodiazepines included lorazepam, 
diazepam, clonazepam, alprazolam, clorazepate, oxazepam, chlordiazepoxide. 
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Appendix 0-12: Baseline characteristics of patients discharged from the hospital after an acute 
coronary syndrome according to being drop out after baseline (TRACE-CORE) 
 
Remaining  Dropout  
p-value  
n=1,573 n=335 
Age (years)   61 [53-69] 59 [50-69] 0.013 
Age group (%)   0.003 
<55 28.29      37.61  
55-64 32.55      28.66  
65-75 26.57       20.00  
≥75 12.59       13.73  
Women (%) 32.61       33.73 0.69 
Race/ethnicity (%)   0.21 
White 78.58       75.82  
Black 15.38       19.10  
Other 6.04        5.07  
Marital status (%)   0.042 
Married/lived as married 59.50       52.54  
Separate/divorced/widowed 28.93      35.52  
Single/never married 11.57       11.94  
Educational attainment (%)   <0.001 
College graduate or higher  26.32       17.61  
Some technical school or college  29.94       23.58  
High school graduates 30.71       28.66  
Less than high school 13.03       30.15  
Insurance coverage (%)   0.001 
Medicare plus private insurance 19.33       17.01  
Private insurance only 50.99       42.39  
Medicare only 12.52       14.93  
Medicaid  9.92      12.54  
Uninsured  7.25       13.13  
Unemployed (%) 57.34       62.69 0.07 
Previously diagnosed (%)    
Anxiety  8.33       10.75 0.16 
Chronic kidney disease 9.47       16.12 <0.001 
Congestive heart failure  12.46       20.60 <0.001 
Coronary artery disease 26.32      28.66 0.38 
Depression  12.40       16.42 0.048 
Diabetes  37.19       42.39 0.08 
Hypertension 75.65       77.01 0.60 
Physiologic findings at admission     
Systolic blood pressure (mmHg) 141 [125-157] 139 [121-158] 0.47 
Diastolic blood pressure (mmHg) 80 [69-90] 80 [70-94] 0.22 
Heart rate (beat/min) 75 [64-88] 78 [68-89] 0.012 
Laboratory findings at admission     
Creatinine (mg/dl) 0.97 [0.81-1.16] 1.01 [0.84-1.27] 0.003 
Glucose (mg/dl) 
126 [105-167] 
       128 [105-
176] 
0.82 
GRACE risk score  93.3 [75.4-111.9] 92.0 [72.6-119.1] 0.79 
Potassium (mmol/l) 4 [3.7-4.3] 4 [3.7-4.3] 0.10 
White blood cell count (109 cell/L) 8.5 [6.8-10.9] 8.7 [6.9-10.9] 0.79 
In hospital complications (%)    
Acute kidney injury 4.58      11.64 <0.001 
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Heart failure/cardiogenic shock 1.97        2.09 0.89 
Atrial fibrillation/flutter  7.82        6.87 0.55 
ACS Type (%)   0.90 
Unstable angina 29.82       28.66  
STEMI  18.37       18.21  
NSTEMI 51.81       53.13  
Reperfusion treatment received (%)   0.003 
Medical treatment 18.94      26.57  
PCI 69.10       60.00  
CABG 11.95       13.43  
Medications at hospital discharge (%)    
Aspirin 96.95       97.01 0.95 
P2Y12 inhibitors  85.95       81.49 0.037 
ACE-I/ARBs  62.05       62.39 0.91 
Beta-blockers 89.89      92.24 0.19 
Statins  87.86       87.46 0.84 
SSRI/SNRI/atypical antidepressants 15.83       21.19 0.017 
Benzodiazepines 28.80       32.54 0.17 
Length of hospital stay (days) 3 [2-5] 3 [2-6] 0.001 
Depression symptoms    
Baseline  
4 [1-8] 
         6 [3-
11] 
<0.001 
Anxiety symptoms    
Baseline  
4 [1-9] 
         6 [2-
13] 
<0.001 
Note: continuous variables were reported in median [interquartile range] 
NSTEMI: non-ST-segment elevation myocardial infarction, STEMI: ST-segment elevation myocardial 
infarction, PCI: percutaneous coronary intervention, CABG: coronary artery bypass graft surgery, ACE-
I/ARBs: Angiotensin converting enzyme inhibitor/Angiotensin receptor blockers, SSRI: selective 
serotonin reuptake inhibitors, SNRI: serotonin and norepinephrine reuptake inhibitors. 
Atypical antidepressants included bupropion, mirtazapine, nefazodone. Benzodiazepines included 
lorazepam, diazepam, clonazepam, alprazolam, clorazepate, oxazepam, chlordiazepoxide. 
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Appendix 0-13: Characteristics of patients discharged from the hospital after an acute coronary 
syndrome according to missing longitudinal data on symptoms of anxiety or depression (TRACE-
CORE) 
 
Complete data Missing data 
p-value  
n=793 n=780 
Age (years)         63 [55-70]         59 [52-67] <0.001 
Age group (%)   <0.001 
<55 23.96 32.69       
55-64 29.76 35.38       
65-75   32.03 21.03      
≥75   14.25 10.90      
Women (%) 31.53 33.72      0.354 
Race/ethnicity (%)   <0.001 
White      83.73 73.33   
Black     10.09 20.77    
Other    6.18 5.90      
Marital status (%)   <0.001 
Married/lived as married 64.31 54.62       
Separate/divorced/widowed    25.98 31.92     
Single/never married     9.71 13.46     
Educational attainment (%)   <0.001 
College graduate or higher  31.40 21.15       
Some technical school or college    31.78 28.08      
High school graduates 29.26 32.18        
Less than high school     7.57 18.59     
Insurance coverage (%)   <0.001 
Medicare plus private insurance   24.09 14.49      
Private insurance only 50.69 51.28       
Medicare only 12.61 12.44        
Medicaid     8.58 11.28      
Uninsured     4.04 10.51      
Unemployed (%)   58.01 56.67     0.591 
Previously diagnosed (%)    
Anxiety      7.57 9.10    0.270 
Chronic kidney disease 9.08 9.87       0.592 
Congestive heart failure  10.21 14.74       0.007 
Coronary artery disease 26.73 25.90      0.706 
Depression    12.36 12.44     0.963 
Diabetes  36.44 37.95       0.537 
Hypertension 74.91 76.41      0.487 
Physiologic findings at admission     
Systolic blood pressure (mmHg)    142 [125-158]        140 [125-156] 0.2691 
Diastolic blood pressure (mmHg)         79 [69-90]         80 [70-90] 0.4565 
Heart rate (beat/min)         74 [64-86] 76 [66-89] 0.0287 
Laboratory findings at admission     
Creatinine (mg/dl) 0.97 [0.8-1.13] 0.97 [0.81-1.19] 0.2952 
Glucose (mg/dl)      125 [104-167]       126 [106-169] 0.6477 
GRACE risk score  95.9[77.5-112.7] 90.7 [72.6-111.2] 0.0056 
Potassium (mmol/l) 4.1 [3.8-4.3] 4 [3.7-4.4] 0.1642 
White blood cell count (109 cell/L) 8.5 [6.8-10.8] 8.4 [6.8-11] 0.7299 
In hospital complications (%)    
Acute kidney injury    3.03 6.15     0.003 
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Heart failure/cardiogenic shock 2.40 1.54       0.221 
Atrial fibrillation/flutter  8.95 6.67       0.091 
ACS Type (%)   0.228 
Unstable angina 29.89 29.74       
STEMI    16.77 20.00      
NSTEMI 53.34 50.26        
Reperfusion treatment received (%)   0.131 
Medical treatment 17.02 20.90       
PCI 70.37 67.82       
CABG 12.61 11.28        
Medications at hospital discharge (%)    
Aspirin 96.85 97.05      0.814 
P2Y12 inhibitors  86.76 85.13       0.352 
ACE-I/ARBs  61.79 62.31       0.833 
Beta-blockers 91.30 88.46       0.062 
Statins      88.02 87.69   0.842 
SSRI/SNRI/atypical antidepressants 14.25 17.44       0.083 
Benzodiazepines 26.61 31.03      0.053 
Length of hospital stay (days)   3 [2-4]          3 [2-5] 0.1289 
Depression symptoms    
Baseline           4 [1-7] 5 [2-10] <0.001 
1 month 2 [1-5]          3 [1-7] 0.0737 
3 months 0 [0-1] 0 [0-2] <0.001 
6 months 0 [0-1] 0 [0-2] <0.001 
12 months 0 [0-1] 0 [0-2] 0.0008 
Anxiety symptoms    
Baseline           3 [1-7] 5 [1-10] <0.001 
1 month 0 [1-5] 2 [0-6] 0.0173 
3 months 0 [0-1] 0 [0-2] 0.0009 
6 months 0 [0-1] 0 [0-2] <0.001 
12 months 0 [0-1] 0 [0-2] <0.001 
Depression symptoms    
Baseline  16.65 25.51       <0.001 
1 month    9.71 16.63     <0.001 
3 months 9.46 14.96       <0.001 
6 months   7.82 16.71      <0.001 
12 months 6.94 15.32       <0.001 
Anxiety symptoms    
Baseline    18.16 25.77     <0.001 
1 month 8.83 14.34        0.002 
3 months 9.33 13.62 0.022 
6 months   8.58 16.46      <0.001 
12 months   9.08 14.44      0.006 
Note: continuous variables were reported in median [interquartile range] 
NSTEMI: non-ST-segment elevation myocardial infarction, STEMI: ST-segment elevation myocardial 
infarction, PCI: percutaneous coronary intervention, CABG: coronary artery bypass graft surgery, ACE-
I/ARBs: Angiotensin converting enzyme inhibitor/Angiotensin receptor blockers, SSRI: selective serotonin 
reuptake inhibitors, SNRI: serotonin and norepinephrine reuptake inhibitors. 
Atypical antidepressants included bupropion, mirtazapine, nefazodone. Benzodiazepines included lorazepam, 
diazepam, clonazepam, alprazolam, clorazepate, oxazepam, chlordiazepoxide. 
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